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Background: Persons who sustain a spinal cord injury (SCI) experience a dramatic loss of 
muscle and bone, and a dramatic increase in adipose tissue. It has been suggested that the muscle 
atrophy, obesity, and sublesional osteoporosis (SLOP) that occurs after SCI is due in part to the 
loss of voluntary control of the skeletal muscles in the lower extremities, impaired energy 
metabolism below the level of the lesion, and cessation of sufficient mechanical strain on bone. 
The prevalence of obesity and SLOP after SCI leads to increased cardiovascular disease and 
fracture risk, respectively. Current body composition screening procedures for the general 
population fail to identify individuals with SCI who are obese or have SLOP. 
Muscle contractions provide physiological loads on bone; thereby a muscle-bone relationship 
is proposed with proportional declines in muscle and bone after SCI. In addition, both positive 
and negative relationships have been proposed between adipose tissue and bone; increased 
skeletal load bearing from excess adipose tissue mass may account for the positive associations 
reported to date. Due to a lack of load bearing activity after SCI, there should be a negative 
association between adipose tissue and bone. 
Objectives: The primary objective is to characterize body composition among adults with 
chronic SCI using valid, reliable, and interpretable measures, and to suggest screening 
procedures for the detection of obesity and SLOP in this population. The secondary objectives 
are to explore the associations between: 1) muscle and bone, and 2) adipose tissue and bone.  
Design and Setting: Cross sectional observational. 
Population: A sample of 16 individuals (13 men, 3 women) with chronic SCI participated in this 
study. The neurological level of lesion ranged from C3-T12, with 9 motor complete and 7 
incomplete SCI. Average±standard deviation for age was 51.12±12.37 years, and duration of 
injury 16.5±7.87 years. An additional 29 individuals with chronic SCI were included when 
exploring the relationship between muscle and bone. Forty-one individuals (31 men, 9 women) 
were included in this analysis; the neurological level of lesion ranged from C2-T12, with 13 
motor complete and 28 incomplete SCI. Average±standard deviation for age was 48.7±13.36 
years, and duration of injury 114.22±10.4 years. 
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Methods: Lean tissue, adipose tissue, and bone tissue were measured via surrogates of body 
adiposity, as well as two different scanning technologies. Lean tissue was assessed via muscle 
cross sectional area (CSA) (mm2) and muscle density (mg/cm3), and measured using peripheral 
quantitative computed tomography (pQCT). Adipose tissue was assessed via body mass index 
(BMI) (kg/m2), waist circumference (WC) (cm), and % body fat, and measured using a floor 
scale, tape measure, and dual energy x-ray absorptiometry (DXA), respectively. Bone tissue was 
assessed via hip, distal femur, and proximal tibia areal bone mineral density (aBMD) (g/cm2) 
using DXA, as well as cortical thickness (mm) and total volumetric bone mineral density 
(vBMD) (mg/cm3) at the 1/3 proximal tibia, and trabecular vBMD (mg/cm3) and total vBMD 
(mg/cm3) at the distal tibia using pQCT. The relationships between muscle and bone, and 
adipose tissue and bone, were determined by correlating muscle CSA with indices of bone 
strength, and indices of obesity with indices of SLOP, respectively. 
Results: The majority of participants had lean tissue values below able-bodied norms (67-100%). 
When using the able-bodied definition of BMI >30 kg/m2, 19% of individuals were obese, 
whereas 63% and 81% were obese when using SCI-specific definitions of BMI >25 kg/m2 or >22 
kg/m2, respectively. One hundred percent of individuals had SLOP using distal femur Z-score, 
and over 50% were at risk of fracture using distal femur fracture threshold of <0.78 g/cm2. Weak 
(r=0.42) to moderate (r=0.57) correlations were found between muscle CSA and indices of bone 
strength, supporting the theory of a muscle-bone unit. No correlations were found between 
adipose tissue and bone.  
Conclusions: Based on the cohort data, we propose that individuals with ≥2 risk factors (female, 
≥60 years of age, duration of injury (DOI) ≥10, tetraplegia, motor complete) should be screened 
for obesity using % body fat from DXA as well as a combination of carefully interpreted SCI-
specific BMI and WC. In addition, these same individuals should be screened for SLOP using a 
distal femur Z-score and fracture threshold from DXA. It is clear that due to the prevalence of 
obesity and SLOP in this population, intervention for prevention or treatment is essential. The 
presence of a muscle-bone unit indicates that muscle atrophy contributes to a reduction in bone 
strength; this is clinically important, as muscle strength is potentially amenable to rehabilitation 
intervention. No correlation was found between adipose tissue and bone. Future work should 
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The present study is an observational investigation of body composition after spinal cord 
injury (SCI), embedded in two larger cross-sectional studies entitled, “Bone Quality in 
Individuals with Chronic Spinal Cord Injury” (CIHR-86521) and “Intermittent Whole Body 
Vibration and Passive Standing for Treatment of Sublesional Osteoporosis after Spinal Cord 
Injury Pilot Study Phase II: Safety and Efficacy Assessment” (ONF-SCI-2006-WAVE-44). A 
portion of the data from the two larger studies was obtained and utilized for the present study. In 
addition, data on bone health among individuals with SCI from several previous studies out of 
Lyndhurst Center, Toronto Rehabilitation Institute, will be utilized to assess one of the secondary 
aims: the relationship between muscle and bone. The main focus of this study is to report body 
composition (lean tissue, adipose tissue, and bone tissue) among a representative sample of 
adults with chronic SCI (injury for >2 years) including both sexes and diverse levels of 
impairment. In addition, to identify individuals who are obese, who have sublesional 
osteoporosis (SLOP), and/or who are at risk of fracture using SCI-specific and able-bodied 
definitions. Finally, screening procedures for detecting individuals at risk of obesity and SLOP 
based on the cohort data will be suggested. Secondary aims will explore potential associations 
between: a) muscle and bone, and b) adipose tissue and bone. 
Outcome measures will include: 1) lean tissue body composition by way of muscle density 
(mg/cm3) and muscle cross sectional area (CSA) (mm2) at the 1/3 proximal tibia; 2) adipose 
tissue body composition by way of body mass index (BMI) (kg/m2), waist circumference (WC) 
(cm), and whole body % fat; and 3) bone tissue body composition by way of hip, distal femur, 
and proximal tibia areal bone mineral density (aBMD) (g/cm2), cortical thickness (mm) and total 
volumetric bone mineral density (vBMD) (mg/cm3) at the 1/3 proximal tibia, and trabecular 
vBMD (mg/cm3) and total vBMD (mg/cm3) at the distal tibia.  
The study may benefit the participants by providing them with information regarding their 
current body composition. The study will benefit the rehabilitation community by furthering our 
understanding of the body composition changes that occur after SCI, and recognizing the utility 
of present screening procedures for chronic disease in this population. In addition, the results 
from this study will broaden our understanding of the associations between muscle and bone, and 





Substantial muscle atrophy occurs after spinal cord injury (SCI). A decrease in muscle 
quantity (muscle cross sectional area [CSA]) and a decrease in muscle quality (change in fiber 
type, change in contractile proteins, decrease in muscle density) both contribute to muscle 
atrophy associated with SCI. It has been reported that a 45% to 80% reduction in muscle CSA (1, 
2) occurs post-injury, which may impact the protective effect muscle contractions have on bone 
strength (3). A shift towards type II muscle fiber type (4-7) in addition to a shift towards myosin 
heavy chain (MHC) type II contractile proteins (2, 8, 9) have also been reported post-injury, 
resulting in highly fatigable muscle that may be difficult to activate for future functional use. The 
loss of muscle CSA and the decrease in muscle density results in less muscle available for 
glucose uptake, and therefore insulin resistance and obesity-related complications occur. Thus, 
muscle atrophy may cause reduced bone strength as well as augmented obesity-related 
complications after SCI. 
In the able-bodied population, obesity is reaching epidemic proportions in both developed 
and developing countries; over the last 20 years obesity has become the most prevalent 
nutritional problem in the world (10). Obesity can be defined as an excess of whole body adipose 
tissue that frequently results in a significant impairment of health. Obesity is a chronic disease 
itself and creates an internal atherogenic milieu, and is a major risk factor for many subsequent 
chronic and non-communicable diseases. Obesity is considered to be a dominant factor in the 
development of cardiovascular disease (CVD), the leading cause of death in the United States 
and a major cause of disability. In 2004, 36% of all deaths in the United States were due to CVD 
(11) such as stroke, peripheral vascular disease, and type II diabetes mellitus (DM). In 2008 it 
was reported that the direct medical care expenditure for type II DM and obesity was more than 
$150 billion (US) (12). A subpopulation at an increased risk of becoming obese are those with 
SCI due to the dramatic lean tissue loss and adipose tissue gain post-injury (13, 14). Individuals 
with SCI may be obese without the physical presence of obesity due to the drastic body 
composition changes. The percentage of body weight as adipose tissue mass is 8-18% higher in 
persons with SCI versus age-, height-, and/or weight-matched able-bodied control subjects (15). 
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The decrease in lean tissue, loss of voluntary control of skeletal muscles, and reduction of 
weight-bearing activity following SCI results in insufficient mechanical strain on the bones of 
the lower extremities. Sublesional osteoporosis (SLOP) is a complication that can occur with 
paralysis; excessive bone resporption paired with little or no bone formation results in dramatic 
decreases in bone mineral density (BMD) of the hip and knee region following injury. 
Individuals with SCI experience a 3% to 4% per month decline in areal BMD (aBMD) of the hip 
and knee region for 12-18 months post-injury (16, 17). This reduction in aBMD results in an 
increased propensity for lower extremity fragility fracture; fragility fractures develop in 25-46% 
of persons living with chronic SCI and SLOP (18). There is a reported 2.8 times increased 
relative risk of fracture for each one standard deviation decrement in aBMD T-score at the 
femoral neck in men with SCI (19). Fragility fractures result in increased morbidity, increased 
attendant care and healthcare costs, and in extreme cases lower extremity amputation (20-22).  
Several factors affect the severity of muscle atrophy, obesity, and SLOP among individuals 
with SCI, including sex, age, duration of injury (DOI), neurological level of injury (NLI), and 
American Spinal Injury Association Impairment Scale (AIS) classification. AIS classification 
differentiates between an individual with a motor complete injury (AIS A-B) and one with an 
incomplete injury (AIS C-D). This has important implications for lower extremity body 
composition and functional ability; much of the literature makes a distinction among individuals 
with SCI based on the completeness of their injury. In addition to demographic and impairment 
characteristics, physical inactivity has been suggested as a factor affecting body composition. 
Studies have reported that individuals who participate in physical activity are less likely to be 
obese in the able-bodied population (23-26) as well as after SCI (27, 28). Further, studies have 
reported that physical activity should be advocated for the prevention of osteoporosis, and 
implemented to reduce the likelihood of falling and its associated morbidity and mortality, in the 
able-bodied population (29); no published literature shows that physical activity prevents or 
treats SLOP after SCI.  
Mechanostat theory suggests that bone strength is adapted to meet mechanical needs (30). 
Muscle contractions provide large physiological loads on bone, and therefore a relationship 
between muscle size and bone strength has been proposed (3). Pronounced muscle atrophy 
occurs following SCI, and so this muscle-bone relationship may help explain the high incidence 
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of fracture after SCI. If this relationship exists, it may be important clinically to test muscle size 
or strength as a predicting factor of osteoporosis and/or fracture risk. 
Increasing biological and epidemiological evidence suggests a possible relationship between 
adipose tissue and bone. Excess adipose tissue may lead to obesity, while diminished bone tissue 
may lead to osteoporosis; both obesity and osteoporosis are both complex chronic diseases that 
share a pathophysiologic linkage (31). This may help explain the high incidence of both chronic 
diseases among individuals with SCI. Exploring the relationship between obesity and 
osteoporosis may expand our understanding of both chronic diseases independently, as well as 
the physiological basis of the association between them. In addition, determining a relationship 
between adipose tissue and bone may be clinically important since adipose tissue mass is a 
potentially preventable risk factor for fracture after chronic SCI. 
1.2: Gaps in the Literature 
The literature to date provides a good overview of body composition changes after SCI. 
However, the measurement sites and measurement techniques used to observe or quantify the 
changes to lean tissue, adipose tissue, and bone tissue vary across studies, making it difficult to 
compare or generalize findings. This observational study will characterize body composition 
among adults with chronic SCI using valid, reliable, and interpretable measures; care has been 
taken to ensure the validity and reproducibility of novel measures.  
The SCI-specific definitions for obesity (13, 32, 33) and SLOP or fracture risk (34, 35) are 
recent and continue to be open to discussion, and therefore not yet widely accepted. 
Consequently, limited studies identify individuals with SCI as being obese or having SLOP using 
tools specific to the SCI population. Current body composition screening procedures for the able-
bodied population fail to identify individuals with SCI who are obese or have SLOP; however, 
some able-bodied definitions may be used among the SCI population if carefully and cautiously 
interpreted. As mentioned above, the completeness of injury has important implications for lower 
extremity body composition and functional ability. This observational study will determine the 
number of individuals with chronic SCI who are obese or have SLOP, taking into account the 
completeness of injury (motor complete [AIS A-B] vs. incomplete [AIS C-D]), based on SCI-
specific and able-bodied definitions. Further, based on the cohort data, this study will suggest 
screening procedures for detection of obesity and SLOP after SCI. 
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A positive relationship between lean tissue and BMD has been proposed among the able-
bodied population (3, 33, 36) as well as among individuals with SCI (33, 37). The studies among 
individuals with SCI utilized dual energy x-ray absorptiometry (DXA) technology, which 
provides a 2-dimensional view of bone and a composite of BMD and bone geometry. Due to the 
unique patterns of bone loss following SCI, it may be interesting to look at the relationship 
between lean tissue and different indices of bone strength using a technology that can provide 
values for trabecular bone and cortical bone separately. Peripheral quantitative computed 
tomography (pQCT) provides 3-dimentional images that can measure size, shape, and mineral 
density of bone, and was shown to predict failure load at the radius more accurately than DXA 
(38, 39). In addition, pQCT allows for the analysis of muscle CSA, which is considered an 
acceptable surrogate of muscle strength (3, 40). This study will explore the association between 
muscle and bone among individuals with chronic SCI using pQCT technology. 
Both positive (41-43) and negative (44) relationships between adipose tissue mass and BMD 
have been proposed among the able-bodied population; few studies have looked at the 
relationship among individuals with SCI. Due to the increase in whole body and regional adipose 
tissue post-SCI and consequent increase in insulin and estrogen production, both hormones that 
contribute to increased bone mass, there may be a positive relationship between adipose tissue 
and BMD (45-51). However, it is recognized that a central contributor to bone strength is the 
gravitational and mechanical loading effect of weight bearing or ambulation. Due to the 
decreases in muscle and bone in parallel with increases in adiposity, as well as the lack of weight 
bearing or ambulation among individuals with SCI, there may be a negative relationship between 
adipose tissue and BMD. This study will explore the association between adipose tissue and 
bone among adults with chronic SCI. 
The findings from this study will increase our understanding of the body composition 
changes that take place after SCI, provide preliminary screening suggestions for detection of 
obesity and SLOP in this population, and improve our understanding of the link between muscle 
and bone, as well as adipose tissue and bone. 
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1.3: Research Objectives 
1.3.1: Primary Objectives 
O1a: To characterize body composition among individuals with chronic SCI using the following 
outcomes: 1) lean tissue: muscle density (mg/cm3) and muscle CSA (mm2) at the 1/3 proximal 
tibia; 2) adipose tissue: body mass index (BMI) (kg/m2), waist circumference (WC) (cm), whole 
body % fat; and 2) bone tissue: hip, distal femur, and proximal tibia aBMD (g/cm2), cortical 
thickness (mm) and total volumetric BMD (vBMD) (mg/cm3) at the 1/3 proximal tibia, and 
trabecular and total vBMD (mg/cm3) at the distal tibia. 
O1b: To determine the number of individuals with chronic SCI who are above and below able-
bodied normative values for muscle CSA and muscle density. In addition, to determine the 
number of individuals with chronic SCI who are obese, who have SLOP, and/or who are at risk 
of fracture using SCI-specific and able-bodied definitions.  
O1c: To suggest screening procedures for detection of obesity and SLOP based on cohort data 
describing the prevalence of obesity and SLOP after SCI. 
1.3.2: Secondary Objectives 
O2: To explore the association between muscle CSA and indices of bone strength (cortical bone 
CSA, cortical thickness, total BMC, total vBMD; trabecular vBMD) among a representative 
sample of adults with chronic SCI. 
O3: To explore the association between indices of obesity (WC, BMI, % body fat) and indices of 
SLOP (distal femur aBMD, distal tibia trabecular vBMD) among a representative sample of 
adults with chronic SCI.  
1.4: Research Hypotheses 
1.4.1: Primary Hypotheses 
H1b: Significant body composition changes occur following SCI. A dramatic reduction in lean 
tissue and increase in adipose tissue mass (13, 33, 52-54), a significantly higher % body fat 
compared to BMI-matched controls (52, 54-57), a greater WC (53), and a rapid decline in aBMD 
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(58-64) and vBMD (65, 66) in the lower extremities have all been reported following SCI. 
Individuals with motor complete (AIS A-B) SCI experience greater lean tissue losses, adipose 
tissue gains, and bone tissue losses when compared to persons with incomplete (AIS C-D) SCI 
(67-71). It is hypothesized that a high proportion of individuals with SCI will have low 
muscle CSA, low muscle density, be obese, have SLOP, and be at risk of fracture. More 
specifically, it is hypothesized that individuals with motor complete (AIS A-B) SCI will 
have more adverse body composition measures than those with incomplete (AIS C-D) SCI. 
Further, it is hypothesized that individuals with SCI will not appear to be at risk for 
obesity when using the able-bodied BMI definition of >30 kg/m2, but will be characterized 
as obese when using SCI-specific cutoffs of >22 kg/m2 or >25 kg/m2. 
1.4.2: Secondary Hypotheses 
H2: Muscle CSA is a factor that may be used to characterize muscle atrophy. Indices of bone 
strength at the 1/3 proximal tibia and distal tibia may represent SLOP after SCI. It is 
hypothesized that there will be a positive correlation between muscle CSA and indices of 
bone strength (cortical bone CSA, cortical thickness, total BMC, total vBMD, trabecular 
vBMD) among a representative population of individuals with chronic SCI. 
H3: WC, BMI, and % body fat are all factors that are used to define obesity. The distal femur 
and proximal tibia are the primary sites of fracture after SCI (22, 72, 73), and the distal femur is 
a more precise and reliable measure of aBMD than the proximal tibia when using DXA (74). In 
addition, it has been reported that fracture risk after SCI can be predicted from a fracture 
threshold at the distal tibia (35). Therefore, these indices of obesity (WC, BMI, % body fat) will 
be individually correlated with indices of SLOP (aBMD at the distal femur, trabecular vBMD at 
the distal tibia). It has been reported that excess adipose tissue may have deleterious effects on 
bone (44, 75-79) when the mechanical loading effect is statistically removed (44). Due to the 
body composition changes in combination with the lack of weight bearing or ambulation, it is 
hypothesized that there will be an inverse relationship between indices of obesity (WC, 
BMI, % body fat) and indices of SLOP (distal femur aBMD, distal tibia trabecular vBMD) 




2.1: Overview of Background 
Individuals with SCI are perhaps at greater risk than any other segment of the population for 
muscle loss, adipose tissue gain, and bone loss. These dramatic body composition changes as a 
consequence of the neurological injury and physical inactivity may predispose individuals with 
SCI to obesity and sublesional osteoporosis (SLOP) post-injury (13, 80). The severity of body 
composition changes post-SCI is further affected by the completeness of injury (AIS A-B vs. 
AIS C-D) (67-71).  
This chapter defines SCI, describes the body composition changes that take place post-injury, 
discusses measurement of body composition after SCI, and identifies SCI-specific and able-
bodied definitions for obesity, SLOP, and fracture risk. Subsequently, the association between 
muscle and bone, as well as between adipose tissue and bone, will be explored. 
2.2: Spinal Cord Injury 
The American Spinal Injury Association (ASIA) defines SCI as “any injury within the neural 
canal below the level of the foramen magnum up to and including the cauda equina” (81). The 
spinal cord is situated within the spine, both of which are made up of segmental levels but do not 
necessarily correspond with one another. An individual can break their spine without sustaining a 
spinal cord injury, if only the vertebrae are damaged.  
Causes of spinal cord damage can be either trauma (vehicular accidents, falls, gun shot 
wound, etc.) or disease (polio, spinal bifida, etc.). According to the Canadian Paraplegic 
Association, an estimated 900 Canadians sustain a traumatic SCI each year (82). The estimated 
total number of persons living with traumatic SCI in Canada is 36,000 (83), resulting in an 
estimated Canadian SCI prevalence of 1/10,000. Vehicular collision accounts for 35% of these 
injuries, while falls or industrial accidents account for 21.8% (82). Traumatic SCI predominately 
affects young adults between the ages 18-47, with a 4:1 ratio of men to women. A SCI is 
described by the NLI (cervical, thoracic, lumbar) and by the AIS (AIS A-D). The AIS is a 





Table 1: American Spinal Injury Association Impairment Scale  
Letter Complete/Incomplete Definition 
A Complete No motor or sensory function is preserved in the sacral regions S4-S5 
B Incomplete Sensory but not motor function is preserved below the neurological level and includes the sacral segments S4-S5. 
C Incomplete 
Motor function is preserved below the neurological level, 
and more than half of key muscles below the neurological 
level have a muscle grade less than 3. 
D Incomplete 
Motor function is preserved below the neurological level, 
and at least half of key muscles below the neurological level 
have a muscle grade of 3 or more. 
E Normal Motor and sensory function are normal. 
 
A simple means of interpreting the AIS with regards to upper motor neuron lesions is as 
follows: individuals with AIS A and B injuries (motor complete) with no voluntary movement of 
the legs are wheelchair bound about their home and community; individuals with AIS C injuries 
(incomplete) may achieve ambulation in their home, but may use a wheelchair for mobility in the 
community; and most individuals with AIS D injuries (incomplete) are able to achieve 
ambulation in their home and community (84). 
Diverse sensory, motor, and autonomic impairments result from various levels and severities 
of injury. Damage or loss of function to the cervical segments of the spinal cord results in 
tetraplegia, or impaired function in the arms, legs, trunk, and pelvic organs. Damage or loss of 
function to the thoracic, lumbar, or sacral segments of the spinal cord results in paraplegia, or 
impaired function in the legs, trunk, and/or pelvic organs. A complete SCI (AIS A) refers to the 
absence of any neurological function (motor and sensory) below the level of the lesion, including 
the fourth and fifth sacral segments. An incomplete SCI (AIS B-D) refers to any preservation of 
motor and sensory function below the level of the lesion, including sacral sparing (85).  
Some individuals with SCI can walk to a degree, while others are dependent on wheelchairs 
or other supportive devices. Further to sensory and motor losses, impotence and various degrees 
of urinary and fecal incontinence are common; catheters and/or a bowel management program 
are utilized to address these problems. Other autonomic effects of lesions above T6 may include 
the inability to regulate blood pressure effectively such as orthostatic hypotension, impaired 
thermoregulation, inability to sweat below the level of the lesion, and chronic pain. The majority 
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of individuals with SCI are fairly continent with involuntary urinary or bowel evacuation 
prevented with medication, catheters, and/or bowel management programs. 
2.3: Lean Tissue after Spinal Cord Injury  
2.3.1: Lean Tissue Changes after Spinal Cord Injury 
Dramatic losses in the quantity and quality of skeletal muscle occur following SCI. A 45-
80% muscle loss of the lower extremities has been reported in the acute phase after complete 
(AIS A) SCI, and a 24-31% lower muscle CSA of the lower extremities was reported in the 
chronic phase among individuals with incomplete (AIS C-D) SCI when compared to able-bodied 
controls. Skeletal muscle atrophy has been shown to be related to decreased muscle density, or 
the accumulation of intramyocellular adipose tissue (IMCAT) among individuals with complete 
and incomplete SCI (86, 87). The proposed rationales for a decrease in quantity and quality of 
skeletal muscle mass are multi-factorial, including: 1) psychosocial factors such as depression or 
isolation (15); 2) prolonged inactivity; and 3) skeletal muscle denervation of the lower 
extremities. 
The decrease in quantity and quality of skeletal muscle mass contributes to the prevalence of 
both obesity and SLOP. The reduction in muscle can result in decreased metabolic rate and 
increased adipose tissue storage if energy intake is not adjusted relative to energy expenditure 
(88). In addition, the predominant peripheral action of insulin and 85% of total glucose uptake 
occurs in skeletal muscle (89, 90). Therefore, decreased quantity and quality of skeletal muscle 
mass following SCI has been suggested to be the largest contributor to hyperglycemia, peripheral 
insulin resistance, and consequently: 1) facilitated glucose oxidation over fatty acid oxidation; 2) 
stimulated synthesis of very low density lipoprotein cholesterol (VLDL-c) in the liver; and 3) 
enhanced storage of triglycerides in adipose tissue (91). This atherogenic internal environment 
contributes to obesity and obesity-related complications. Further, decreased quality of lean tissue 
by means of increased IMCAT or decreased muscle density has been reported to be an 
independent risk factor for obesity-related diseases such as type II diabetes mellitus (DM) (92). 
The decrease in both quantity and quality of lean tissue that occurs following SCI results in a 
decrease or cessation of physiological loading on bone. Based on the mechanostat theory, this 
results in decreased bone strength and osteoporosis (3). 
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Table 2: Changes in Skeletal Muscle Following Spinal Cord Injury 
Study Population: 
N(M/F); type 
DOI Methods Findings 
Scelsi et al., 
1982 (93) 
22 (M), complete para 1-17mo.  Biopsy of RF • 1-4mo: ↓ type II muscle fiber diameter 
• 4-9mo: ↓ type I and type II muscle fiber diameter 
• 10-17mo: ↓ type I muscle fiber no., ↑ type II muscle fiber no. 
Lotta et al., 
1991 (8) 
10 (M), age 16-54yrs, 
complete para C5-T1 
1-10mo. Biopsy of G, S • 1-6mo: ↓ type IIa muscle fiber diameter 
• 8-10mo: ↓ type I and relative↑ type IIb muscle fiber no.; ↑ type II 
MHC 
Martin et al., 
1992 (5) 
5 (3M, 2F), age btw 22-
38yrs, complete C6-T4 
2-11yrs. Biopsy of TA • ↓ CSA 
• ↓ type I muscle fiber no. 
• ↓ SDH (48-67%) 
Round et al., 
1993 (6) 
7 (M), age 24-47yrs, 
para 
11mo-9yrs. Biopsy of VL • 5 participants showed marked or predominance of type II muscle 
fiber 
• 2 participants with shortest DOI showed preserved type I muscle 
fiber  
Burnham et 
al., 1997 (9) 
12 (8M, 4F), mean age 
22.4yrs, C6-T8 
0.5 to 219mo. Biopsy of VL • ↑ type II MHC btw 4-6wks 
• predominance of type II MHC and stable at ~70mo. 
Gerrits et al., 
1999 (94) 
7 (6M, 1F), age btw 22-
46yrs, AIS class A-C, 
C5-T5 
 
1-21yrs Isometric quad 
contractions via ES  
• ↑ type II muscle fiber characteristics (faster rates contraction and 
relaxation; ↑ fatigability) 
• ↓ force-generating capacity 
Castro et al., 
1999 (2) 
15 (13M, 2F), age btw 
18-45yrs, complete C6-
L1 (median injury T1) 
>6mo. Biopsy of VL • ↓ CSA (-33%); 
• ↓ type I, IIa, IIax+IIx muscle fiber diameter (-27-56%) 
• ↓ type IIa muscle fiber no. 
• ↑ type IIax+IIx muscle fiber no. 
• ↑SDH & GPDH  
Castro et al., 
1999 (1) 
14 (12M, 2F), AIS class 
A (C6-T10) (median 
injury T4); 10 para, 4 
tetra 
>6mo.  MRI of leg and thigh  
 
• ↓ avg CSA (-45-80%) 
• ↓ avg CSA of G (-24%), S (-12%); QF (-16%), hamstrings (-14%); 
adductor (-16%) 
Talmadge et 
al., 2002 (95) 
6 (M), age 18-45yrs, 
complete, AIS class A, 
C6-T10; 5 para, 1 tetra 
>6mo. Biopsy of VL 
 
• Muscle fibers mismatched for SERCA and MHC 
• ↑ type IIx MHC (all SERCA1) 
• high proportion of type I MHC and type IIa with both SERCA1 and 
SERCA2 
Ditor et al., 
2004 (96) 
6 (5M, 1F), avg age 
32yrs, complete para T4-
1-19yrs. Biopsy of VL and AD 
 
• ↓ [Na+K+-ATPase] in VL compared to AD (-66%) 
• neg. correlation btw [Na+K+-ATPase] and DOI 
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T10, AIS class A   • higher proportion of type I muscle fiber than expected 
Modlesky et 
al., 2004 (56) 
8(M), complete C6-L1 >2yrs MRI and DXA of thigh • ↓ muscle mass and FFST 
• ↓ muscle mass in FFST (-15%) 
• ↑ %fat 
DOI = duration of injury, ASIA = American Spinal Injury Association Impairment Scale, CSA = cross sectional area, ES = electrical stimulation, para = 
paraplegic, tetra = tetraplegic, no. = number 
MRI = magnetic resonance imaging, DXA = dual energy x-ray absorptiometry, FFST = fat free soft tissue 
VL = vastus lateralis, G = gastrocnemius, S = soleus, TA = tibialis anterior, QF = quadriceps femoris, AD = anterior deltoid 
SDH = succinic dehydrogenase, GPDH = alpha-glycerophosphate dehydrogenase, PFK = phosphofructokinase, MHC = myosin heavy chain 
SERCA = sarco(endo) plasmic reticulum calcium-adenosine triphosphatase, [Na+K+-ATPase] = Sodium, potassium-adenosine triphosphatase concentration 
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Following motor complete acute SCI (~6 months post-injury), a rapid and drastic decline in 
the quantity and quality of the denervated lower extremity musculature occurs. Muscle cross 
sectional area (CSA), muscle fiber type, muscle density, contractile proteins, and metabolic 
enzyme levels are affected following acute SCI. As mentioned above, one study reported a 45% 
to 80% decrease in quadriceps muscle CSA within the first 6 months post-SCI (1). Another study 
reported a ~60% reduction of muscle CSA within the first 6 weeks (2). The differences in 
reported muscle atrophy between studies could be attributed to varied methodology of muscle 
biopsy (histochemical) (2) vs. imaging (metabolic) (1). While most studies do not show a 
histochemical muscle fiber type transfer from type I to type II within the first 6 months of SCI, a 
transformation within type II muscle fibers from type IIa to type IIax+IIx has been observed (2). 
Interestingly, atrophy of primarily type II muscle fiber within the first 4 months post-injury, 
atrophy in both type I and type II between 4 and 9 months post-injury, and atrophy of primarily 
type I muscle fiber >12 months post-injury has been observed (8, 93). Regarding muscle quality, 
individuals with incomplete SCI were reported to have greater IMCAT accumulation (decreased 
muscle density) when compared to able-bodied controls six weeks post-injury (86). In addition to 
the dramatic decline in muscle CSA and muscle density, there are changes in the contractile 
capacity of muscle in the acute state of SCI.  
Several studies have observed a shift within 6 months post-injury towards type II myosin 
heavy chain (MHC) (2, 8, 9). Myosin is the molecular motor of skeletal muscle, and is comprised 
of two MHC; the faster type II MHC is central to speed, energy demand, and efficacy of 
contraction. The transformation to faster MHC suggests that the muscle would have faster 
contractile speed and become highly fatigable. Ultimately, the increase in faster fibers impacts 
the ability to activate the paralyzed muscle or participate in endurance activity, which affects 
future functional use of the muscle. Finally, a change in metabolic enzyme levels, most notably 
succinic dehydrogenase (SDH; a marker of aerobic-oxidative capacity) and α-glycerophosphase 
dehydrogenase (GPDH) (2, 97) occurs following acute SCI. Observations of muscle quantity and 
quality suggest that acute motor complete SCI results in rapid and significant decreases in 
muscle CSA and a loss of MHC contractile protein (1, 2).  
In the chronic stages of SCI (>2 year post-injury), muscle CSA continues to deteriorate but at 
a slower rate (9). One study compared lower extremity muscle CSA using MRI among 17 
individuals with incomplete SCI 13 years post-injury to 17 age-, weight-, sex-, and height-
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matched controls, and found that the individuals with SCI had 24%-31% lower muscle CSA than 
controls. The muscle CSA differences were highest in the thigh muscles (~31% in the quadriceps 
femoris) compared with the lower leg muscles (~25% in the tibialis anterior) (98). While 
contractile proteins and metabolic enzyme levels continue to change, the predominant skeletal 
muscle modifications that occur late after injury are muscle fiber type shifts from type I to type II 
muscle fiber (4-7). Several studies have reported an almost complete absence of type I muscle 
fibers 2-11 years post-injury (5-7, 99). Just as with the shift towards faster MHC type II, the shift 
towards faster muscle fibers (type II) may affect the person’s ability to activate the paralyzed 
muscle or participate in endurance activity, which in turn may reduce their functional abilities. In 
contrast to the studies showing a shift towards type II muscle fibers, one study looking at 
histochemical muscle fiber type change among 22 paraplegic SCI participants 1-17 months post-
injury observed type I muscle fiber atrophy, but with a marked decrease in the relative 
percentage of type II muscle fibers (93). Perhaps a shift towards type I muscle fiber would be 
observed following a longer duration of injury. A higher proportion of type I muscle fibers has 
been reported (96), however the participants in this study experienced considerable muscle 
spasticity which may have facilitated the preservation of type I muscle fibers and explain the 
contrary findings (100). 
The NLI and AIS have implications on the severity of skeletal muscle loss and related 
complications (reduced metabolic rate and energy expenditure, impaired muscle function, 
obesity, type II DM, etc.). Individuals with complete SCI (AIS A) have reduced energy 
expenditure when compared with controls, and individuals with a higher NLI (i.e. tetraplegia) 
have reduced basal metabolic rates as well as significantly lower total daily energy expenditure 
when compared to individuals with a lower NLI (i.e. paraplegic) (101, 102). In addition, 
individuals with complete tetraplegia are more susceptible to obesity-related diseases such as 
type II DM; a recent study reported that 73% of participants with complete tetraplegia had type II 
DM compared to 24-44% of those with incomplete lesions or with paraplegia (103).  
Age and sex are further factors affecting muscle quantity and quality; as individuals age, lean 
mass decreases (sarcopenia) (104) and IMCAT increases (105). Therefore, older individuals 
have decreased muscle quantity and quality. Among individuals with SCI, advancing age has 
been associated with a lower percent lean mass (33). In addition, women with SCI tend to have a 
lower lean mass than men (106). 
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In summary, the dramatic decline in skeletal muscle quantity and quality following SCI 
contributes to or helps precipitate insulin resistance and reduces mechanical strain on bone, 
ultimately contributing to further complications including obesity and SLOP.  
2.3.2: Measures of Lean Tissue after Spinal Cord Injury 
2.3.2.1: Muscle Cross Sectional Area  
Since the dramatic reduction in muscle CSA that occurs post-SCI may have implications for 
the development of both obesity and SLOP (3, 88), it may be useful to include a measure of 
muscle CSA when assessing body composition. Muscle CSA can be measured using pQCT. To 
analyze a pQCT scan for muscle CSA, various thresholds are used to separate the 
muscle/bone/skin pixels from adipose tissue pixels, to determine the pixels belonging to bone, 
and finally to determine pixels belonging to skin. The bone and skin areas are then subtracted 
from the muscle/bone/skin area to get total muscle CSA (mm2). In an unpublished study, 
reproducibility of pQCT muscle CSA at the 1/3 proximal tibia was assessed in 10 able-bodied 
participants scanned twice with a 2-week time interval between the first and second set of scans. 
The muscle area was determined with precision errors less than 3%1. This same study compared 
muscle CSA derived from a pQCT scan to muscle area derived from clinically used spiral CT 
among 18 able-bodied adults (9 men, 9 women), and reported that pQCT is just as reliable as a 
clinical CT scanner when determining muscle CSA. 
2.3.2.2: Muscle Density  
A decline in muscle density may contribute to the development of both obesity and SLOP 
after SCI (92, 107, 108). Therefore, including a measure of muscle density may be a valuable 
addition to the assessment of body composition post-SCI. Muscle density reflects the lipid 
content of skeletal muscle, and so a lower muscle density is associated with greater adipose 
tissue infiltration in skeletal muscle. Several studies have reported adipose tissue infiltration in 
skeletal muscle by measuring muscle density as a surrogate (109, 110). Muscle density is 
expressed in mg/cm3 and has been shown to be a valid measure of IMCAT (111). Although one 
recent unpublished abstract reported that muscle density measured with pQCT Stratec XCT 2000 
                                                
1 CL Gordon, CE Webber, LF Beaumont. Accuracy and Precision Error of Muscle Cross-sectional Area Measured 
Using Peripheral Quantitative Computed Tomography in Adults. Abstract. 
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software from a pQCT scan is the most variable soft tissue to assess due to the difficulty in 
obtaining accurate segmentations and its physical nature within the muscle2, some studies have 
published muscle density data via pQCT scan analyses among able-bodied persons (112). By 
obtaining a single calf-muscle slice using the present pQCT technology, a relatively small depot 
of skeletal muscle adipose tissue is obtained in comparison to other studies analyzing IMCAT 
via CT measures of the mid-thigh (111, 113, 114). However, a recent study has shown that CT 
muscle density of the mid-thigh is significantly correlated with muscle density of the calf (115).  
The combination of a measure of muscle CSA and muscle density may provide a clinically 
meaningful approach of determining lean tissue body composition among individuals with SCI. 
2.3.3: Normative Values for Lean Tissue Measures after Spinal Cord Injury 
In this study, we have chosen muscle CSA and muscle density as measures of lean tissue 
among persons with SCI because of the dramatic loss of muscle quality and quantity documented 
to occur after SCI. 
2.3.3.1: Muscle Cross Sectional Area  
The unpublished study mentioned above that compared muscle CSA from pQCT to muscle 
area from a clinically used spiral CT reported an overall mean ± SD of muscle CSA among the 
18 participants (9 men, 9 women) to be 7156.8 ± 1112.5 mm2, using a voxel size of 0.4mm. Data 
from our lab using pQCT to assess muscle CSA at the 1/3 proximal tibia among 12 able-bodied 
persons of Caucasian descent (3 men, 9 women), average age 25.5±2.54, reported an overall 
mean ± SD of 7019.6±1331 mm2. Female specific muscle CSA was 6918.4±933.53 mm2, and 
male specific muscle CSA was 7323.0±2464.46 mm2. There are a few limitations to using this 
data as normative values for the present study such as: it was a convenience sample and therefore 
not likely representative, the participants were not carefully screened for health issues that may 
compromise muscle, and it was a small sample of young participants (all under 30 years of age). 
However, it may be useful as preliminary normative data among a Caucasian able-bodied 
population, to compare with the muscle CSA from the SCI population in the present study. To 
                                                
2 F Caronzo, D Inglis, KA Beattie, C Gordon, JD Adachi. MRI vs. pQCT Imaging: Comparing the Variability 
Between Various Segmented Soft Tissue Areas. Abstract. 
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the author’s knowledge, no published values of muscle CSA at the 1/3 proximal tibia using 
pQCT among individuals with SCI exist. 
2.3.3.2: Muscle Density  
One recent study looked at muscle density using pQCT among 471 individuals belonging to 
eight large multigenerational families of African ancestry. They reported a lower skeletal muscle 
density in women (72.4 mg/cm3) than men (75.2 mg/cm3) indicating a greater skeletal muscle 
adipose tissue infiltration among the female participants. In addition, they reported an age-effect 
on muscle density such that a 10% and 12% difference in muscle density among men and 
women, respectively, were found between the youngest group (18-29 years) and the oldest group 
(≥60 years) (110). Earlier studies reported similar findings of a lower skeletal muscle density 
among elderly Caucasian and African American women compared to men (116, 117), and lower 
skeletal muscle density in the elderly compared to the young (118). Studies have also shown a 
BMI-effect on muscle density such that a one-unit increase in BMI is associated with 1-5% 
decrease in muscle density (110). Although there is some literature looking at muscle density 
among populations of certain disease states (119-122), published muscle density values among 
individuals with SCI do not exist.  
2.4: Adipose Tissue after Spinal Cord Injury  
2.4.1: Adipose Tissue Changes after Spinal Cord Injury 
Although it is well documented that an increase in adipose tissue mass occurs after SCI (13, 
33), the determination of true adipose tissue gain following SCI is restricted as it is difficult to: 
1) obtain baseline measurements within the first 2-4 weeks post-injury, and therefore true lean 
tissue losses and adipose tissue gains within the first year remain largely unmeasured; and 2) 
differentiate between an adipose tissue gain owing to paralysis rather than genetics or 
environmental factors (123). However, a study carried out among 8 pairs of male monozygotic 
twins showed a significant difference in total body adipose tissue mass and percent adipose 
tissue per unit BMI among the SCI twin compared to their able-bodied twin (37), suggesting a 
direct relationship between SCI and adipose tissue gain. Obesity is present in more than two 
thirds of those with SCI (13, 14), with adipose tissue mass reported as 8-18% higher among 
those with SCI when compared to able-bodied controls (15). Several studies have reported 
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significantly higher percent adipose tissue mass among adults with SCI when compared to BMI-
matched controls using DXA (54-57) or deuterium dilution (52). Given that obesity can exist in 
the absence of weight gain or the physical appearance of obesity among individuals with SCI, 
there is a frequent failure to recognize obesity among the SCI population. This lack of 
recognition is due to the decrease in lean tissue mass and the increase in adipose tissue mass that 
occurs post-injury (13, 33, 52-54).  
The increase in adipose tissue post-SCI can be attributed to the additive effects of poor 
nutritional habits and a reduction in energy expenditure (52, 101, 124, 125). The reduction of 
energy expenditure is due to several factors: 1) prolonged physical inactivity; 2) reduced basal 
metabolic rate due to loss of metabolically active skeletal muscle (13); and 3) impaired energy 
metabolism below the level of the lesion (124). Physical activity has been shown to suppress 
obesity among the able-bodied population (24-26), as well as after SCI (126-128). However, the 
physiological (diminished work capacity, neurogenic conditions, impaired thermoregulation, 
autonomic dysreflexia, impaired ventilatory capacity, spasticity, etc.), psychological (lack of 
motivation, interest, depression), and physical (cost or location of physical activity, accessibility 
of facility, knowledgeable instructors, etc.) barriers unfortunately result in low participation in 
physical activity among a large proportion of individuals with SCI. 
Impairment characteristics are associated with energy expenditure, and consequently affect 
body adiposity. Twelve to 54% lower basal energy expenditure than controls, depending on NLI 
and AIS, have been reported due to the relative loss of metabolically active muscle tissue (88, 
101, 102). With regards to the NLI, a person with a higher level of injury will experience greater 
reductions in energy metabolism, consequently increasing adipose tissue gain. For example, 
individuals with tetraplegia exhibit lower levels of serum high-density lipoprotein cholesterol 
(HDL-c) (signifying increased adiposity) when compared to those with paraplegia (67, 69, 103). 
With regards to the AIS, a greater decrease in energy expenditure is seen among individuals with 
motor complete SCI (AIS A-B) when compared to individuals with incomplete SCI (AIS C-D) 
because muscle activity is further limited in motor complete SCI. For example, individuals with 
motor complete injuries have lower levels of serum HDL-c when compared to those with motor 
incomplete injuries (67-69). With regards to DOI, during the acute stage of an SCI individuals 
tend to lose weight due to major trauma resulting in hypermetabolism and hypercatabolism (125, 
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129, 130). Following the acute phase and continuing into the chronic phase, decreased energy 
expenditure results in adipose tissue gain. 
The distribution of adipose tissue has implications for the severity of obesity and frequency 
of obesity-related diseases (131-133). The risks associated with excess adiposity may in fact be 
more a function of where the adipose tissue is distributed rather than of the total amount of 
adipose tissue. Adipose tissue can be stored in several body compartments: directly beneath the 
skin (subcutaneous, SAT), within the abdomen bound by the parietal peritoneum (visceral, 
VAT), or within the muscle (inter-muscular adiposity [IMAT] directly beneath the fascia lata; 
and intramyocellular adipose tissue [IMCAT] within the muscle itself (120, 122, 134)). Both 
VAT and SAT contribute to abdominal obesity; however, excess VAT is more strongly 
associated with obesity-related disorders such as insulin resistance than other adipose tissue 
compartments in the able-bodied population (114, 135-139). Recent studies have shown both 
IMAT (92, 114, 140) and IMCAT (141-143) to be strongly correlated with complications of 
obesity, in particular insulin resistance. A strong relation between increased IMCAT and insulin 
resistance was found to be independent from central and overall adiposity among able-bodied 
persons (141, 144, 145). In addition, the reduction of lean tissue associated with an increase in 
IMCAT decreases the capacity for glucose uptake. One study reported that IMCAT may be a 
contributing factor to impaired glucose tolerance and type II DM after SCI (87).  
Race (146-149), age (150, 151), sex (152), as well as SCI (13, 53) are all known to affect 
adipose tissue and adipose tissue distribution. To elucidate, obesity disproportionately affects 
populations of African origin (148, 149). As individuals age, adipose tissue mass accrues, and 
therefore older individuals have a higher percentage adipose tissue mass in the absence of weight 
gain (153). For a given BMI, men are reported to have more lean mass, and women to have 
higher adipose tissue mass. In addition, men have been found to have more VAT, while women 
carry more SAT (152).  
Individuals with SCI have a unique distribution of adipose tissue (13, 53), including 
increased waist circumference and increased VAT (53), as well as increased IMAT (87) when 
compared to able-bodied controls. A recent study reported individuals with SCI to have 58% 
greater mean VAT than matched able-bodied controls after differences in weight were accounted 
for (53). The effect of excess adipose tissue, particularly VAT and IMCAT, on the internal 
environment directly contributes to an atherosclerotic milieu and an increased risk of obesity-
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related disorders. Understanding the distribution of adipose tissue may therefore contribute to a 
more insightful and comprehensive assessment of body composition among persons with SCI. 
2.4.1.1: Adipose Tissue and the Internal Environment 
Adipose tissue is an active endocrine organ. Excess adipose tissue has recently been 
associated with pro-thrombosis, a state in which there is a risk of inappropriate blood 
coagulation. Adipose tissue directly secretes plasminogen activator inhibitor (PAI-1), and 
circulating lipids stimulate hepatic secretion of thrombin-activatable fibrinolysis inhibitor 
(TAFI). Both are pro-thrombotic agents that inhibit fibrinolysis, and both are directly associated 
with adipose tissue mass (154-156). Consequently, an increase in adiposity increases the risk of a 
pro-thrombotic state.  
Adipose tissue also produces and secretes hormones including leptin, adiponectin, and 
resistin. These adipokines are not only associated with adipose tissue mass, predominantly VAT, 
but also interact with other tissues and cells in the body [including bone cells]. A disruption in 
the secretion, function, and balance of adipokines occurs in the course of obesity resulting in 
changes in metabolic processes and accelerated atherosclerosis. Research looking at fasting 
levels of adipokines among individuals with SCI is limited; 3 studies have reported higher levels 
of serum leptin among men with SCI when compared to able-bodied controls (157-159), and one 
study showed a tendency for higher levels of serum adiponectin among men with SCI (157).  
Abdominal adipose tissue, in particular VAT, is an independent predictor of obesity-related 
diseases such as CVD (160, 161). In both men and women, VAT deposits of >130 cm2 are 
associated with disturbances of glucose-insulin homeostasis as well as pro-atherogenic changes 
in the plasma lipoprotein-lipid profile (162). VAT secretes large amounts of circulating pro-
inflammatory cytokines including interleukin-6 (IL-6) and tumor-necrosis factor-alpha (TNF-α) 
(163). Both IL-6 and TNF-α ultimately cause low-grade vascular inflammation and the synthesis 
of C-reactive protein (CRP) (164, 165), which has been linked to increased risk of type II DM 
and CVD in able-bodied and SCI (166, 167). Due to the associations between: 1) VAT and CRP, 
and 2) CRP and CVD, some scientific literature has reported CRP levels as an indicator of 
increased VAT (168, 169). However, given that CRP levels may be elevated for several reasons 
after SCI other than excess VAT including bladder infection or pressure sores, these associations 
may be inaccurate. In addition, the hypertriglyceridemia of abdominal obesity leads to low 
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density lipoprotein cholesterol (LDL-c) production, increased apolipoprotein B (ApoB) levels, 
and reduced HDL-c levels. The metabolic environment created by VAT contributes to obesity 
and obesity-related complications (170). 
VAT and SAT may not completely explain the atherogenic internal environment resulting 
from obesity. There has been a recent increase in interest in IMCAT due to its association with 
type II DM (142, 171-174) and impaired muscle function (116, 150). There appears to be an age- 
(110, 118), sex- (110, 116, 117) and race-effect (109, 175-177) on IMCAT. The underlying 
mechanism for increased accumulation of adipose tissue within the muscle is unknown, but some 
studies have suggested decreased fat oxidation (178), decreased lipolysis (179), and/or increased 
fatty-acid uptake and higher expressions of fatty acid transport proteins (180) as possible 
rationales. Obesity alone may explain and perpetuate the harmful internal environment causing 
and resulting from IMCAT among able-bodied persons. Among individuals with SCI, however, 
this detrimental internal environment occurs due to a combination of obesity, physical inactivity, 
and impaired energy metabolism below the level of the lesion.  
2.4.2: Measures of Adipose Tissue after Spinal Cord Injury 
Understanding the methods for measuring body composition and their underlying 
assumptions and limitations is key to interpreting body composition data after SCI. Individuals 
with SCI are perhaps at greater risk of obesity than any other segment of the population. The 
literature regarding the prevalence of obesity among persons with SCI is poorly substantiated 
(13), and there are inadequate established guidelines for accurate classification of obesity in this 
population. Due to the differences in body topography between individuals with SCI and able-
bodied persons, techniques developed for the able-bodied population to assess and monitor body 
composition cannot be used to accurately quantify body composition in the SCI population. The 
following sections describe several measures of body composition, and discuss their utility in the 
SCI population. 
2.4.2.1: Hydrostatic Weighing, Air Displacement Plethysmography, Bioelectrical 
Impedance Analysis, Skin-Fold Measures 
Hydrostatic weighing holds assumptions that are violated among those with SCI including: 1) 
the components of fat-free mass (water, protein, mineral) are proportionally constant to a 
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reference non-SCI cadaver; and 2) residual lung volumes are larger in the able-bodied and 
therefore inaccurately measured for persons with SCI (181).  
Air displacement plethysmography and bioelectrical impedance analysis (BIA) both rely on 
body density predicted from hydrostatic weighing and violates these same assumptions. In 
addition, BIA assumes constant hydration and therefore does not take into account any fluid 
shifts that may occur among the SCI population such as lower-extremity edema or venous 
pooling (13). Further, a study looking at different body positions during BIA among the SCI 
population found that a seated position deviated the most from an accurate body composition 
prediction (182). Finally, BIA devices tend to lose accuracy in severely obese persons. 
Anthropometric equations developed for skin-fold measurements are also based on hydrostatic 
weighing assumptions, and are population-specific. A similar equation has not been developed or 
validated for the SCI population. Due to considerable alterations in fluid states and substantial 
changes in muscle mass and bone density post-SCI, the validity of these aforementioned 
measures is questionable (183-187).  
2.4.2.2: Body Mass Index  
BMI (weight [kg] divided by height [m] squared) is often used among the able-bodied 
population as a screening tool for diagnosing obesity-related disorders (188); there is a link 
between BMI and chronic disease among the able-bodied population (189). In fact, BMI is often 
used to define obesity among the general population. The main assumption when using BMI 
guidelines is that body mass, adjusted for height squared, is closely related to body adiposity and 
therefore morbidity and mortality (188). However, the relationship between BMI and body 
adipose tissue content varies with age, sex, and race; therefore, cut-off points could be lower or 
higher than the WHO recommended figures.  
When the WHO criteria are used among individuals with SCI, obesity may not be accurately 
categorized (33, 54, 190); variable relationships have been found between BMI and chronic 
disease in people with SCI (191-194). Individuals with SCI are frequently said to be normal or 
overweight instead of obese since the mass of adipose tissue is less than that of lean tissue; 
therefore, this inaccurate categorization contributes to an underestimation of obesity.  
A further cause for inaccurate categorization of BMI among individuals with SCI is 
measurement error during weight and height calculation. To obtain a BMI measurement, a 
 
 24 
wheelchair scale is typically used for attaining a weight measurement, but obtaining a height 
measurement is more difficult. Many studies have used subject height recall (33, 192, 193), 
however this is not recommended as recalled height and measured length have been found to be 
inconsistent among those with SCI regardless of age or DOI (195). Measured length can be used 
as an alternative, as it has been shown to be closely associated with height (196).  
2.4.2.3: Waist Circumference  
BMI does not provide information regarding the distribution of adipose tissue, which is an 
important factor when assessing health risks resulting from obesity. Therefore, in combination 
with BMI, it is important to consider the location of adipose tissue when determining body 
composition. Adipose tissue in the abdominal region, particularly VAT, is strongly correlated 
with risk factors for CVD. WC is positively correlated with abdominal adipose tissue content, 
and is an accurate, reliable, and reproducible surrogate measure of VAT.  
In large epidemiological studies, WC has been shown to be strongly, significantly, and 
independently correlated with several obesity-related complications. In addition, the able-bodied 
literature (197-200) as well as the third National Health and Nutrition Examination Survey (201) 
found that WC was more strongly correlated with three obesity-related risk factors than BMI. 
The location of a WC measurement is controversial. WC is measured among able-bodied persons 
in a standing position with a measuring tape placed around the abdomen in a horizontal plane 
after normal expiration. According to the World Health Organization (WHO), the location of the 
measurement is the midpoint between the lower border of the rib cage and the iliac crest. 
According to the National Institute of Health (NIH), the location of the measurement is at the 
superior border of the iliac crest. A prior study reported equally high reproducibility with WC 
values measured at four different sites of immediately below the lowest rib, at the narrowest 
waist, midpoint between the lowest rib and the iliac crest, and immediately above the iliac crest 
(202). The narrowest waist (found to be at the lowest rib) was reported to be the most frequently 
recommended, as the site of the lowest rib is easy to identify, even in obese persons (202).  
Among those with SCI, WC measured below lowest rib after normal expiration in a supine 
position showed high reproducibility, and appeared to be a simple means of obtaining the WC 
measurement (53). This method of WC measurement is highly correlated with VAT among a 
cohort of individuals with complete, incomplete, paraplegic and tetraplegic SCI (53). Research 
 
 25 
continues to support a relationship between WC and chronic disease risk such as obesity and 
CVD in the SCI population (15, 203).  
2.4.2.4: Percent Body Fat  
BMI and WC are both surrogates for assessing body adiposity due to the practical and cost 
effective nature of obtaining these measures. However, more accurate means of assessing body 
adiposity exist, such as magnetic resonance imaging (MRI) or DXA. MRI has the capability to 
maximize the contrast between different tissues (i.e. muscle, bone, cartilage, etc.), allowing them 
to be analyzed separately. However, MRI is expensive, associated with long weight times, not 
often readily available, and not always possible for use among individuals with SCI due to metal 
implants. 
DXA has been used to assess body composition among several different populations 
including SCI (55, 158, 204-208); DXA can measure total as well as regional lean tissue mass, 
adipose tissue mass, and % body fat (209-211). Appropriate software must be used to determine 
the lean and adipose tissue mass from DXA scans. The principle of DXA is such that x-ray 
beams of two peak energies are produced (low and high-energy photons), and are attenuated 
differently in bone and soft tissue. When the x-ray or photon source is placed on one side of the 
person [or object], the intensity and energy of the beam on the other side of the person [or object] 
is related to its thickness, density, and chemical composition. The differences in attenuation 
through bone, lean tissue, and adipose tissue reflect the different chemical composition of each 
component. The energies used are selected to optimize separation of the mineralized and soft 
tissue components of the area analyzed. With increasing photon energy, the difference in 
attenuation properties for each tissue decreases. Based on theoretical and experimental studies, it 
has been found that if the low-energy photon is 40 keV and the high-energy photon is in the 
range of 70-100 keV, estimates of the bone mass and overlaying soft tissue mass can be 
calculated (212-214).  
From a whole-body DXA scan, bone-containing pixels make up 40-45%, and the remaining 
pixels are used to estimate the body’s adipose tissue-to-lean tissue ratio. Concern has been 
expressed that the relative adipose tissue-to-lean tissue ratio is thus based on sampling only one-
half of the whole body, as well as hydration status of the persons lean tissues (215). However, 
DXA-derived values for lean and adipose tissue mass have been compared with multi-
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compartment models with good agreement (216). Estimates for the bone, lean, or adipose tissue 
mass have since been theoretically shown to be unaffected by a person’s hydration status (217-
220). Radiation doses from DXA depend on the site measured (i.e. whole body vs. lumbar 
spine), but are typically ~30 µSv, which is less than doses received annually from background 
radiation (2500 µSv). The radiation dose of ~30µSv is roughly equal to the dose of radiation 
received over 3 day by every Canadian from natural sources of radiation in the environment. 
DXA is costly and time consuming, and requires trained personnel to administer the scan. In 
addition, for accurate comparison within person, the same DXA equipment, acquisition, and 
analysis protocols should be used. 
2.4.3: Defining Obesity after Spinal Cord Injury 
In this study, we have chosen BMI, WC, and body fat % via DXA as measures of adiposity 
among persons with SCI. Rationale for using BMI includes its widely accepted use and 
simplicity of attaining the measure, as well as recently suggested SCI-specific BMI cut-offs for 
defining obesity. Rationale for using WC includes the simplicity of attaining the measure, as well 
as the importance of characterizing adipose tissue location for obesity and obesity-related 
diseases. Rationale for using % body fat via DXA includes its widely accepted use and reliability 
in determining body composition. 
2.4.3.1: Body Mass Index  
BMI is widely used due to its simplicity and correlation with WHO criteria of underweight 
(BMI <18.5), normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9), obese class I (BMI 
30-34.9), obese class II (BMI 35-39.9), and obese class III (BMI >40) classification among able-
bodied persons (221).  
In studies of persons with chronic SCI, mean BMI values range from 20 to 27 kg/m2 (33, 54, 
191, 192, 222-224). A study comparing BMI to four-compartment modeling [reported to 
accurately assess body composition among individuals with SCI (225)] showed that 77% of 
those with paraplegia had a mean BMI in the normal range (BMI 18.5-24.9 kg/m2), but a body 
fat % in the obese range (≥26% for men, ≥39% for women) (181). Other SCI studies reporting 
both BMI and body fat % showed a mean BMI in the low 20s and a mean body fat % in the 
obese range (33, 37, 52, 54-56, 181, 222, 226, 227). Seventy-seven adults with chronic SCI 
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underwent anthropometric measures (body fat % via BIA, and BMI), and reported a BMI cutoff 
of 30 kg/m2 failed to identify 73.9% of obese participants. A recent study has identified lowered 
BMI cutoffs to better identify obese persons with SCI; it was concluded that a BMI cutoff of >22 
kg/m2 is appropriate for identifying individuals with SCI who are at high risk of obesity and 
obesity-related chronic diseases (32). Further, two groups of experts in the field of body 
composition after SCI, independent of each other, suggested a BMI cutoff of >25 kg/m2 (13, 
33)3,4 to identify individuals with SCI who are obese. 
2.4.3.2: Waist Circumference  
It has been reported that a WC of >95 cm is a good surrogate for a visceral adipose depot of 
>130 cm2 among able-bodied men and women (228). The NIH states that the WC at which there 
is an increased relative risk of CVD is defined as >102 cm (>40 in) for men, and >88 cm (>35 in) 
for women, and should be used in conjunction with BMI among able-bodied persons with a BMI 
between 25 and 29.9 kg/m2 (229). There are no SCI-specific values for WC measurement. 
2.4.3.3: Percent Body Fat  
As DXA measures are often expensive and not readily available, there are no universally 
accepted % body fat ranges to define overweight and obesity. However, several researchers have 
suggested % body fat ranges for normal, overweight, and obesity; one study reported a working 
approach to developing age-, race- and sex-specific % body fat ranges that correspond to 
published BMI guidelines for underweight (<18.5), overweight (≥25) and obesity (≥30) (230). 
Body fat % was measured via DXA, and BMI was calculated via height and weight among 1626 
men and women of three groups (Caucasian, African American, and Asian) and three age 
categories (20-39, 40-59, and 60-79 years). The authors developed an equation to convert DXA 
to a 4-compartment % body fat, and for Caucasian men aged 20-39 they reported a % body fat 
range of 8-20% for normal weight (BMI 18.5-24.9 kg/m2), 21-25% for overweight (25-29.9 
kg/m2), and ≥26% for obese (BMI ≥30 kg/m2). For Caucasian women aged 20-39 they reported 
a % body fat of 21-32% for normal weight, 33-38% for overweight, and ≥39% for obese (230). 
                                                
3 Personal Communication: Dr. David Gater; 2009 Congress on Spinal Cord Medicine and Rehabilitation, 
September 22-26, Dallas, TX. 
4 Personal Communication: Dr. Ann Spungen; 2009 Congress on Spinal Cord Medicine and Rehabilitation, 
September 22-26, Dallas, TX 
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2.5: Bone Tissue after Spinal Cord Injury  
2.5.1: Bone Tissue Changes after Spinal Cord Injury 
The WHO has defined osteoporosis as a skeletal disease characterized by “low bone density 
and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility 
and susceptibility to fracture.” (231). It has been well accepted that the most powerful and 
measurable determinant of fracture risk is the amount of bone in the skeleton measured by bone 
mineral density (BMD) or bone mineral content (BMC) (232, 233). The prevalence and relative 
risk of fracture increases dramatically with decreased BMD (234).  
A subpopulation that is at an increased risk of developing osteoporosis and subsequent 
increased fracture risk are those with SCI. The sites where fractures most commonly occur 
following SCI are the distal femur and tibia, the proximal tibia, the femoral and tibia shaft, and 
less commonly the femoral neck and bones of the foot (235, 236). Over 90% of the reported 
fractures occur in the distal femur or proximal tibia (22, 72, 73). The majority of fragility 
fractures occur due to minor trauma events such as a transfer from a wheelchair or rolling over in 
bed (237). Fractures after SCI can lead to increased morbidity, decreased functional mobility, 
and increased attendant care and healthcare costs.  
Regional changes in areal and volumetric BMD, changes in the shape and structure of the 
long bones of the legs, and alterations in bone CSA have been reported following SCI (61, 238), 
all of which predispose individuals with SCI to SLOP. SLOP is distinct from postmenopausal 
osteoporosis in its rate of onset, rate and severity of decline in BMD, etiology and associated 
regional fracture risk, micro-architecture of bone, and skeletal distribution (239-242). It is 
characteristic of persons with traumatic SCI to experience a 3%-4% per month decline in aBMD 
of the hip and knee region within 12-18 months post-injury (243, 244). Several studies have 
reported that the rapid decline in aBMD following injury amounts to the hip, distal femur, and 
proximal tibia being 28%, 37-43%, and 36-50% below that of age-matched able-bodied 
individuals (58-64).  
The decline in vBMD of the hip and knee region is predominantly peri-articular, with relative 
preservation of cortical bone and reduced trabecular volume (65, 66). In agreement with these 
findings, a recent study measured vBMD using pQCT among persons at least 5-7 years post-
injury, and found a 54% and 73% loss in trabecular vBMD of the distal femur and distal tibia, 
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respectively (245). Further, a study using MRI to examine bone health among individuals with 
chronic motor complete SCI reported reduced bone volume, reduced trabeculae number, and 
increased spacing between bone trabeculae at the distal femur and proximal tibia compared to 
controls (246, 247). These findings suggest that trabecular bone is more affected than cortical 
bone following SCI. One study looked at vBMD of the tibia among 6 individuals with acute 
tetraplegia (12 months post-injury) and reported a decrease of 15% and 7% of trabecular and 
cortical vBMD, respectively (238). Another study looking at vBMD of the tibia among 8 
individuals with chronic SCI (>2 years post-injury) found a decrease of 35.3% and 12.9% in the 
trabecular and cortical compartments, respectively (248). Further, one study reported exponential 
decay in cortical wall thickness of the tibial and femoral shafts, but not cortical vBMD following 
SCI (245). 
Some studies suggest that aBMD stabilizes by 1-2 years after SCI, at 25-50% below that of 
able-bodied peers, in the hip and knee regions (244, 249). A more recent study reported that a 
new steady-state was reached at 50% of the mean value of a reference group after 3 years in the 
femur, and at 40% after 5 years in the tibia distal epiphysis. This same study reported a decrease 
in cortical wall thickness but not cortical vBMD, reaching a steady state after 5 years at 65% and 
7 years at 70% below that of reference values in the femoral and tibial shafts, respectively (245). 
Contrary to these studies, recent investigations support a continual decline in aBMD with time 
post injury of 3% per year, and that a steady-state of lower extremity bone mineral homeostasis 
is not reached (64, 65, 240, 250). 
Contributing factors to changes in bone mass/BMD may include: decreases in lean tissue, 
loss of voluntary control of skeletal muscles, reduction of weight-bearing activity, increased 
renal calcium excretion and reduced intestinal absorption of calcium, hormonal and metabolic 
changes, alterations in blood flow, and alterations in the immune system (251-255). The relative 
importance of each of these factors has not been clearly established. Physical activity has been 
shown to have potential in modifying fracture risk among the able-bodied population (256), but 
no rehabilitation intervention to date has documented a sustained increase in hip or knee region 
BMD among individuals with SCI (257-261), or demonstrated ability to prevent fractures. It is 
plausible that in the small sample sizes examined to date, the short duration of treatment 
interventions and insufficient mechanical stresses failed to induce osteoblast activity or decrease 
osteoclast activity, resulting in the lack of treatment effects. 
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Five factors that should be taken into consideration when determining an individuals’ risk of 
developing SLOP and subsequent fracture risk following SCI: age (≥60 years), sex (female), 
DOI (≥10 years), NLI (tetraplegia), AIS (motor complete), and muscle CSA (234, 262-265). The 
incidence of fracture has been reported to be 2-6% per year, and increases with the duration of 
SCI (18, 266); one study out of the United States reported a 14% incidence of fractures among 
those injured 5 years, 28% incidence among those injured 10 years, and a 39% incidence among 
those injured 15 years (18). Although individuals with complete paraplegia and complete 
tetraplegia will experience similar bone loss of the lower extremities, individuals with paraplegia 
have been reported to have a higher incidence of lower extremity fracture when compared to 
those with tetraplegia (22), perhaps due to the higher use of manual wheelchairs and higher 
occurrence of independent transfers, and therefore a greater chance of falls. Individuals with 
complete SCI tend to lose more bone than those with incomplete SCI (70, 71), and therefore 
fractures are more common among individuals with complete injuries (72).  
Accurate assessments of these changes are costly and difficult, but are important when 
assessing SLOP and risk of fracture. 
2.5.2: Bone Tissue Measures after Spinal Cord Injury  
2.5.2.1: Areal Bone Mineral Density and Fracture Threshold/Breakpoint 
DXA can be used to measure total and regional BMD. In fact, DXA is the most widely 
applied method of measuring bone density. DXA measurements allow for the mass of bone 
mineral to be calculated in the whole body as well as regionally, and expressed as an areal bone 
density (aBMD) in grams per square centimeter (g/cm2). DXA is most commonly used to scan 
the lumbar spine, femoral neck, and whole body; the areas of the lumbar spine and femoral neck 
are the sites of common fracture among able-bodied individuals. Due to the fact that cortical 
bone is greater when looking at a whole body scan, BMD and therefore fracture risk may not be 
accurately represented at specific sites. 
To interpret aBMD results from a DXA scan, appropriate race- and sex-matched aBMD 
reference ranges are required (267, 268). The participant’s result can then be expressed as a T-
score, which has been validated for whole body aBMD. A T-score compares actual bone density 
to sex-matched peak bone density of young adults, reported as a number of standard deviations 
below the average, with one digit (e.g. -2.3). The WHO defines a T-score of >-1 as normal, a T-
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score of -1 to -2.5 as low bone density, a T-score of <-2.5 as osteoporosis, and a T- score of ≤-
2.5 in conjunction with at least one or more fragility fractures as severe osteoporosis. These 
criterion, as well as those from the National Osteoporosis Foundation (NOF) of the United States 
for osteoporosis is intended to diagnose postmenopausal women only (269, 270).  
The International Society for Clinical Densitometry (ISCD) provides expanded guidelines to 
include postmenopausal women, premenopausal women, and men under the age of 50. 
According to ISCD, T-scores are preferred and the WHO densitometric classification is 
applicable for postmenopausal women and men aged 50 and older. For women prior to 
menopause and for men younger than age 50, however, Z-score are preferred. A Z-score 
compares actual bone density to the bone density of age-, weight-, sex-, and race-matched 
persons. ISCD classifies a Z-score of -2.0 or lower to define, “below the expected range for age”, 
and a Z-score of above -2.0 to define, “within the expected range for age” (271).  
Unfortunately, there is no specific protocol for assessing or interpreting aBMD among 
individuals with SCI. The distal femur and proximal tibia, skeletal sites most likely to be 
fractured after SCI (22, 72, 73), are not included in routine scanning protocols using DXA. To 
predict fracture risk of the paralyzed legs, it is important to measure aBMD at the sites in which 
most of the fractures occur. Therefore, it is important to have a protocol for scanning and 
criterion for interpreting the scan at the distal femur and proximal tibia sites. Barriers to BMD 
testing among individuals with SCI contribute to the lack of available protocols for assessing 
bone health in this population. Barriers may include scanner design, limited accessibility, 
increased typical scanning time, and increased staff necessary (272). However, one recently 
published article evaluated the precision of a DXA scanning protocol for measuring BMD at the 
knee in SCI, as well as specifically the distal femur vs. proximal tibia. It was reported that the 
determination of BMD at the knee was precise, and was free of many sources of variation 
common in scanning the spine (day-to-day changes in abdomen contents related to gut peristalsis 
and meals). In addition, it was reported that BMD assessed at the distal femur was more precise 
than at the proximal tibia among individuals with SCI (74).  
An alternative means for determining osteoporotic risk and therefore fracture risk is to assess 
the fracture threshold, the aBMD at a specific site below which fractures begin to occur, or 
fracture breakpoint, the aBMD value at which the majority of fractures occur. Fracture threshold 
values using DXA have been established among postmenopausal able-bodied women at 0.97 
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g/cm2, 0.95 g/cm2, and 0.92 g/cm2 (Z scores of -2.3, -2.4, and -2.2, respectively) at the lumbar 
spine, femoral neck, and intertrochanteric region of the femur, respectively (273).  
Fractures are uncommon at the spine or hip among individuals with SCI, and so fracture 
thresholds at the lower extremity sites, specifically at the knee, would be more beneficial for this 
population. A recent study established a fracture threshold and a fracture breakpoint at the knee 
among a cohort of individuals with SCI. Data from 168 participants (141 had no lower extremity 
fractures, and 27 had sustained a lower extremity fracture post-injury) was reviewed, and aBMD 
at the knee was compared in the non-fracture group vs. the fracture group. It was reported that 
when the knee was used as a proxy for the entire lower extremity, the fracture threshold was 0.86 
g/cm2 and the fracture breakpoint was 0.49 g/cm2. This article reported a fracture threshold at the 
knee of 0.78 g/cm2, and fracture breakpoint of 0.49 g/cm2. The article noted that a low aBMD at 
the knee cannot entirely predict who will fracture; risk factors important to consider, in this 
order: low BMD (<0.78 g/cm2), complete paraplegia, sex (female), prior fracture, DOI, and age 
(34). 
2.5.2.2: Volumetric Bone Mineral Density and Fracture Threshold 
A tool for bone assessment that is beginning to receive more attention due to its ability to 
calculate volumetric densities (mg/cm3) is pQCT. The cross-sectional approach of pQCT allows 
for the separation between cortical and trabecular bone compartments with calculation of 
separate vBMD, as well as assessment of various bone geometric properties such as trabecular 
spacing or cortical thickness. Individuals with chronic SCI experience a unique pattern of bone 
loss including substantially reduced trabecular vBMD, relatively preserved cortical vBMD, and 
reduced cortical thickness. Therefore, separate trabecular and cortical measures directly at the 
bone sites most prone to fractures may prove to be invaluable in predicting fracture risk in this 
population. Like DXA, pQCT is costly, time-consuming, and requires experienced personnel to 
administer the scan. In addition, the repositioning of an individual when obtaining a pQCT scan 
may affect the reproducibility of measures; however, a recent study reported a good precision of 
pQCT in measurement of the tibia (274). 
Assessing fracture thresholds at sites of common fracture after SCI using pQCT technology 
would be beneficial for assessing fracture risk. Accelerated bone loss and fractures often 
manifest at skeletal sites with a higher proportion of trabecular bone, and trabecular vBMD has 
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been shown to be associated with fractures in cross-sectional studies. A recent study has 
suggested fracture thresholds of the femur and tibia among individuals with SCI (35). Bone 
measurements and fracture assessments were obtained from 99 individuals with motor complete 
SCI (para- and tetraplegic, AIS A and B), 27 of whom had sustained a fracture of the lower 
extremities. The participants with and without femur fractures had mean femur trabecular 
vBMDs of 84.8 ± 23.8 mg/cm3 and 116.8 ± 26.0 mg/cm3, respectively. The participants with and 
without tibia fractures had mean tibia trabecular vBMDs of 46.9 ± 21.8 mg/cm3 and 68.4 ± 22.4 
mg/cm3, respectively. The data from this study implied a fracture threshold at approximately 110 
mg/cm3 at the distal femur and 70 mg/cm3 at the distal tibia (35). 
2.5.3: Defining Sublesional Osteoporosis after Spinal Cord Injury 
In this study, we have chosen hip, distal femur, and proximal tibia aBMD Z-scores from a 
DXA scan to define SLOP. Rationale for using Z-scores at these sites includes the widely 
accepted use of Z-scores among the able-bodied population for defining osteoporosis, as well as 
the importance of assessing SLOP at sites most common to fracture after SCI. In addition, SCI-
specific distal femur aBMD fracture threshold and distal femur aBMD fracture breakpoint from a 
DXA scan were used to determine fracture risk after SCI. Further, distal tibia trabecular vBMD 
fracture threshold from a pQCT scan was used to determine fracture risk after SCI. Rationale for 
using these measures includes the specificity to the present population, as well as the importance 
of characterizing fracture risk at sites most common to fracture after SCI. 
2.5.3.1: Areal Bone Mineral Density and Fracture Threshold/Fracture Breakpoint 
The ISCD guidelines, as mentioned above, are expanded to include premenopausal women 
and men <50 years, and therefore may be more useful than the WHO guidelines for defining 
osteoporosis among subpopulations such as SCI. From a DXA scan, a Z-score of <-2.0 can be 
used to define osteoporosis at the hip, distal femur, and proximal tibia among individuals with 
chronic SCI (271). 
A DXA scan can also provide aBMD values at the hip, distal femur, and proximal tibia. As 
mentioned above, a recent study established a fracture threshold and fracture breakpoint at the 
knee among a cohort of individuals with chronic SCI. The fracture threshold at the distal femur 
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of 0.78 g/cm2 and the fracture breakpoint at the distal femur of 0.49 g/cm2 can be used to predict 
fracture risk among individuals with chronic SCI (34). 
2.5.3.2: Volumetric Bone Mineral Density and Fracture Threshold 
The distal tibia is one of the sites common to fracture after SCI (235, 236). As mentioned 
above, one study determined a fracture threshold at the distal tibia among a cohort of individuals 
with SCI. Using a pQCT scan, the fracture threshold of approximately 70 mg/cm3 at the distal 
tibia can be used to predict fracture risk among individuals with chronic SCI (35).  
2.6: Identifying Risk Factors for Obesity and Sublesional Osteoporosis 
Several factors affect the severity of muscle atrophy, obesity, and SLOP among individuals 
with SCI: sex (female) (275, 276), age (≥60 years) (153, 277), DOI (≥10 years) (275), NLI 
(tetraplegia) (67, 69, 103), and AIS (motor complete) (67-69, 235). As mentioned previously, 
AIS classification differentiates between an individual with a motor complete injury (AIS A-B) 
and one with an incomplete injury (AIS C-D). This has important implications for lower 
extremity body composition and functional ability, and therefore may have a greater contribution 
to adverse body composition changes after SCI than the other risk factors. The relative risk of 
each of the abovementioned factors may be important when applying them as a means of 
identifying individuals at risk of obesity and SLOP. Further elements that may influence the 
prevalence of obesity and SLOP after SCI that should be taken into consideration when applying 
the 5 risk factors described above include: previous fracture, drug intake, dietary intake, level of 
physical activity, and/or socioeconomic status. 
2.7: Muscle-Bone Unit after Spinal Cord Injury 
Both the skeleton and musculature undergo harmonic and concordant physiological growth, 
and in aging these changes are reciprocal. In the able-bodied population, muscle loss is 
associated with increased fracture risk due to various mechanisms including increased bone 
remodelling and alterations in the sense of equilibrium, leading to greater predisposition towards 
falling (278). Both lean tissue loss and bone loss following SCI is common, and these changes 
combined increase the risk of fracture after SCI. Fragility fractures often occur due to minor 
trauma events such as a transfer from a wheelchair or rolling over in bed (237). Due to the 
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substantial human and economic costs of fractures, it is important to understand the mechanisms 
by which bone strength is developed and maintained.  
The mechanostat theory suggests that bone strength is adapted to meet mechanical needs 
(30). It has been proposed that bone quality is made up of baseline bone strength at birth and 
typical peak voluntary mechanical loads. These typical peak voluntary mechanical loads are 
from activities of daily living or from purposeful training. Two types of loading determine the 
strength of bone: direct mechanical loading (walking, running, jumping) and indirect 
physiological loading (muscle contractions). Muscle contractions provide the largest 
physiological loads on bone, and therefore a linear relationship has been proposed between 
muscle size and bone strength (3). Studies have reported associations between an index of 
muscle strength (muscle cross sectional area [CSA]) and indices of bone strength (i.e. BMC, 
BMD) among the able bodied population (3, 33, 36, 279-281), supporting the concept that 
muscle strength is one of the main determinants of the robustness of bone. In the various phases 
of life, the ratio between muscle and bone remains almost constant (282, 283), such that muscle 
loss is one of the main determinants of bone fragility. If a muscle-bone relationship exists, in 
conditions of muscle atrophy such as after SCI, there should be a corresponding decline in bone 
strength.  
Few studies have looked at the muscle-bone relationship among individuals with SCI. One 
study reported a strong association between muscle and aBMC in the legs among individuals 
with incomplete SCI (37), while another reported a strong association between muscle and 
aBMD in the arms among individuals with SCI, regardless of the NLI or AIS (33). These studies 
used DXA that provides aBMD, a 2-dimentional view of bone and a composite of BMD and 
bone geometry. The original muscle-bone unit theory was presented using pQCT, which 
provides a 3-dimentional image that can measure size, shape, and mineral density of bone, and 
was shown to predict failure load at the radius more accurately than DXA (38, 39). pQCT can 
also provide muscle CSA, which is considered an acceptable surrogate of muscle strength (3, 
40). Given that individuals with SCI experience a unique pattern of bone loss including a 
predominant loss of trabecular vBMD and cortical thinning (245), it may be valuable to look at 
the separate components of bone, as well as muscle CSA, using pQCT technology.  
Cortical bone CSA, cortical thickness, total vBMD, and total BMC at the 1/3 proximal tibia, 
and trabecular bone CSA, trabecular vBMD, total vBMD, and total BMC at the distal tibia may 
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be good indices of bone strength to associate with muscle CSA among individuals with chronic 
SCI.  
2.8: Adipose Tissue and Bone after Spinal Cord Injury 
Obesity and osteoporosis are both complex chronic diseases. Both diseases are affected by 
genetic and environmental factors, normal aging is associated with both diseases, and both 
adipocytes and osteoblasts are derived from a common precursor – the mesenchymal stem cell – 
in bone marrow (284). The activation of the peroxisome proliferators activated receptor-γ 
(PPAR-γ) pathway favours differentiation of mesenchymal stem cells into adipocytes over 
osteoblasts (285, 286), while the Wnt signaling pathway inhibits adipogenesis in preadipocyte 
cells (287, 288) and promotes osteogenesis (289-291). Whether a relationship exists between 
obesity and osteoporosis, and the basic mechanisms underlying the relationship are unclear, 
although several potential mechanisms have been proposed to support either a positive or 
negative relationship. Increased skeletal load bearing from excess adipose tissue mass (41-43), 
the association of adipose tissue mass with the secretion of bone active hormones (i.e. insulin, 
amylin, preptin) (46, 292), or the secretion of bone active hormones from adipocytes (i.e. 
estrogen) (47-51), may account for the positive associations reported to date. Absence of load 
bearing (44) may account for the negative associations reported to date.  
A relationship between body weight and bone mass is well represented in the literature; it is 
recognized that a larger body mass (contributed to by both adipose tissue mass and lean mass) 
imposes a greater mechanical loading on bone, and that bone mass increases to accommodate the 
greater load. This relationship is plausible with increasing adipose tissue mass, as the extra 
weight increases the load that the skeleton is required to bear. Clinical observations have shown 
that obesity is associated with increased BMD (41). The reverse has also been shown in that a 
decrease in body weight leads to bone loss (293). Further, many studies have shown that 
adiposity and bone mass are directly correlated (42, 43). It has been reported that individuals 
who lose bone rapidly have significantly lower adipose tissue mass than individuals who lose 
bone slowly (294). One study explored the adipose tissue and bone mass relationship in a cohort 
of healthy postmenopausal women and found that aBMD was more closely related to weight, 
BMI, and adipose tissue mass, and less closely related to lean mass (295). Several other studies 
reported similar results (292, 293, 296). The relationship appears to be dependent on sex (weaker 
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in men) (297), menopausal status (stronger post-menopause) (298), and level of physical activity 
(stronger among sedentary persons) (299).  
It is likely that if adipose tissue mass impacts bone mass, it would do so by modulating 
activity of bone cells. Obesity is associated with hyperinsulinemia, and insulin is a potential 
regulator of bone growth since osteoblasts have insulin receptors (45). In addition, insulin has 
been shown to directly stimulate osteoblast proliferation in vitro (46). It is thought that the direct 
effects of insulin on bone are reinforced by two other hormones, amylin and preptin, that are co-
secreted with insulin. In humans, the high plasma insulin, amylin, and preptin levels may 
increase sex hormones (i.e. estrogen), increase osteoblast activity, and decrease osteoclast 
activity, all pathways that contribute to increased bone mass (292). Further, it has been 
hypothesized that in the able-bodied population, enhanced estrogen production due to adiposity 
may be related to BMD (47-51). 
Contrary to a positive relationship between adipose tissue mass and bone mass, the reverse 
has been reported in the literature. If the mechanical loading effect of total body weight is 
statistically removed, a negative correlation between adipose tissue mass and bone mass is 
found, indicating that excess adipose tissue mass actually has a detrimental effect on bone (44). 
Further research has shown that excessive adipose tissue mass may not protect against decreases 
in bone mass (75-79), and that the risk of osteoporosis is higher for individuals with higher body 
adiposity, independent of body weight (77). One study reported that a higher proportion of 
adipose tissue mass was negatively associated with bone mass among 153 premenopausal 
women (78). Another study among late adolescent women reported that excess weight in the 
form of adipose tissue mass may have a negative effect on adolescent bone (300).  
Persons with chronic SCI have an increase in whole body and regional adiposity (37). The 
increase in adipose tissue may result in hyperinsulinemia, as well as enhance estrogen 
production, thereby providing a protective effect on bone. On the other hand, individuals with 
chronic SCI experience decreases in muscle and bone in parallel with increases in adipose tissue, 
thus presenting a setting in which an inverse relationship between adipose tissue and bone may 
exist. Further, for those individuals with SCI who are unable to weight bear or ambulate, 
reduction of gravitational and mechanical forces may attenuate the association found between 
body weight and bone mass.  
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The current study will investigate the relationship between indices of obesity (BMI, WC, and 
% body fat) and lower limb bone density (distal femur aBMD, distal tibia trabecular vBMD). 
BMI, WC, and % body fat are all used as indices to describe or define obesity. Able-bodied men 
and women are considered overweight with a BMI of 25-29.9 kg/m2 and obese with a BMI of 
≥30 kg/m2 (301). One potential problem with using BMI as an index of obesity is that BMI may 
not necessarily represent obesity per se as it is excessive adipose tissue mass, rather than total 
body weight, that defines obesity. In addition, characterization of overweight and obesity using 
BMI among individuals with SCI is unreliable. However, there is a link between BMI and 
chronic disease among the able-bodied population (189), and adjusted BMI values have been 
published for individuals with SCI such that individuals with chronic SCI and BMI values of >22 
kg/m2 (32) or >25 kg/m2 (13, 33) are considered at high risk of obesity and obesity-related 
chronic diseases. Able-bodied men and women are considered at risk of obesity and obesity-
related diseases (e.g. CVD) with a WC of >102 cm and >90 cm, respectively (301). WC is highly 
correlated with VAT among individuals with SCI (53), and therefore potentially contributes to 
chronic disease risk in this population (228). Able-bodied men and women <40 years of age are 
considered overweight with a % body fat of >20% and >33%, respectively, and are considered 
obese with a % body fat of >25% and >39%, respectively. Excess body adiposity is a widely 
accepted definition of obesity, and is associated with increased chronic disease risk (302). 
Regarding indices of SLOP, over 90% of the reported fractures occur in the distal femur or 
proximal tibia (22, 72, 73), and the distal femur is a more precise and reliable measure of BMD 
than the proximal tibia when using DXA (74). In addition, it has been reported that fracture risk 
after SCI can be predicted from a fracture threshold at the distal tibia (35). Therefore, the aBMD 
at the distal femur site and the trabecular vBMD of the distal tibia are the most appropriate 
measures to correlate with indices of obesity.  
2.9: Summary of Study Rationale and Background 
Dramatic lean tissue losses, adipose tissue gains, and bone tissue losses occur after spinal 
cord injury, predisposing this population to obesity and SLOP. Obesity can lead to many 
secondary complications, most notably cardiovascular disease (CVD), the leading cause of death 
after SCI. Forty-six percent of deaths are due to CVD for individuals 30 years post-injury (303-
305). SLOP can also lead to secondary complications, most notably fracture. The incidence of 
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fracture has been reported to be 2-6% per year, and increases with the duration of SCI (18, 266); 
one study reported a 39% incidence of fracture among those injured 15 years (18). Fragility 
fractures result in increased morbidity, increased attendant care and healthcare costs, and in 
extreme cases lower extremity amputation (20-22). Both obesity and SLOP are influenced by 
demographics (age and sex) and injury related characteristics (DOI, NLI, and AIS). Determining 
the lean tissue, adipose tissue, and bone tissue composition of individuals with SCI is therefore 
important to help understand, manage, and hopefully improve the chronic disease risk of obesity 
and SLOP in this population. Of note, most body composition assessments are developed for the 
able-bodied population, resulting in erroneous categorization among the SCI population. Body 
composition assessment may be achieved via DXA and pQCT, as well as surrogates of body 
adiposity (BMI and WC).  
A relationship between lean mass and bone has been suggested, which may help explain the 
high incidence of SLOP and fracture after SCI. The proposed relationship is such that the 
reduction or cessation of physiological loading from muscle contractions on bone after SCI 
results in deceased bone strength and SLOP (3). Exploring the relationship between muscle and 
bone may expand our understanding of the mechanisms involved in bone loss and fracture after 
SCI.   
A relationship between obesity and osteoporosis has been suggested, which may help explain 
the high incidence of both chronic diseases among individuals with SCI. Exploring the 
relationship between obesity and SLOP may expand our understanding of both chronic diseases 




3.1: Overview of Study Design 
The present study was an observational study on body composition after SCI, embedded in 
two larger studies entitled, “Bone Quality in Individuals with Chronic Spinal Cord Injury” (Bone 
Quality Study) and “Intermittent Whole Body Vibration and Passive Standing for Treatment of 
Sublesional Osteoporosis after Spinal Cord Injury Pilot Study Phase II: Safety and Efficacy 
Assessment” (WBV Study). The main focus of the first larger study is to establish a pilot cohort 
of individuals with chronic SCI; the cohort can create the potential for future prospective 
longitudinal studies evaluating predictors of fracture in the SCI population. Eighty individuals 
with chronic SCI are to be recruited to participate in this larger study; the recruitment is on-
going. Fourteen of these individuals (recruited prior to September 2009) were included in the 
body composition analysis for the present study. The main focus of the second larger study is to 
determine the safety and therapeutic potential of whole body vibration (WBV) on bone health 
after SCI. Ten adult men with chronic motor complete paraplegia are to be recruited to 
participate in this larger study; the recruitment is on-going. Two of these individuals (recruited 
prior to September 2009) were included in the body composition analysis for the present study. 
In addition, muscle CSA and indices of bone strength from a further 29 individuals were 
included when exploring the association between muscle and bone. These data were taken from 
two previous studies out of McMaster University and the University of Waterloo, entitled 
“Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications 
due to Spinal Cord Injury” and “Reproducibility of a New Bone Density Technique”, 
respectively.  
The main focus of the present study was to characterize body composition (lean tissue, 
adipose tissue, and bone tissue) among a representative sample of individuals with chronic SCI 
(injury for >2 years) including both sexes and diverse levels of impairment. Additional 
objectives included: a) determining the number of individuals with chronic SCI who were above 
and below able-bodied normative values for muscle CSA and muscle density; b) determining the 
number of individuals with chronic SCI who were obese, had SLOP, and/or were at risk of 
fracture using SCI-specific and able-bodied definitions; and c) suggesting screening procedures 
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for detection of obesity and SLOP after chronic SCI. Secondary aims were to explore potential 
associations between: a) muscle and bone, and 2) adipose tissue and bone.  
A portion of the data from the larger studies was obtained and utilized for the present study. 
The study visits of consequence for the present observational study were as follows: 
1. A visit to Lyndhurst Center consisting of a medical history questionnaire including 
injury etiology and impairment descriptors; a DXA scan that measured whole body 
% fat as well as hip, distal femur, and proximal tibia aBMD (g/cm2); a WC measure 
(cm), and a height (m) and weight (kg) measure. 
2. A visit to Hamilton Health Sciences’ McMaster University consisting of a pQCT 
scan that measured muscle density (mg/cm3), muscle CSA (mm2), cortical bone CSA 
(mm2), cortical thickness (mm), total vBMD (mg/cm3), and total bone BMC 
(mg/mm) from the 1/3 proximal tibia site, and trabecular bone CSA (mm2), 
trabecular vBMD (mg/cm3), total vBMD (mg/cm3), and total BMC (mg/mm) from 
the distal tibia site. 
3.2: Recruitment and Screening 
3.2.1: Recruitment 
Potential participants for both larger studies were identified through a number of recruitment 
mechanisms including: 1) a poster campaign, 2) online publication on Canadian Paraplegic 
Association (CPA) Ontario website, 3) referral by a rehabilitation service provider, 4) at the 
individual’s request, or 5) with the use of the SCI Long-Term Follow-Up Database. The SCI 
Long-Term Follow-Up Database contains a list of individuals interested in finding out more 
information about ongoing SCI research at Lyndhurst Centre. The Long-Term Follow-Up 
Database contains the contact and demographic information for individuals with SCI who have 
consented to be contacted for the purpose of receiving information about relevant research.  
Prior to data collection, potential participants were required to meet inclusion criteria, as well 
as not meet exclusion criteria. These criteria were different for each larger study. NLI and AIS 
scores were confirmed via an AIS exam done by a physiatrist at Lyndhurst Center, Toronto 
Rehabilitation Institute. The following inclusion and exclusion criteria were required for 




Table 3: Participant Inclusion and Exclusion Criteria for Bone Quality Study 
Inclusion Criteria Exclusion Criteria 
• Able to understand instructions in 
English or has an interpreter that is 
willing to accompany them (e.g. family 
member) 
• A traumatic spinal cord impairment (C2-
T10 ASIA A-D) associated with a stable 
upper motor neuron 
• >1 yr post-injury 
• Ability to give informed consent 
• Age > 18 years 
• Current or prior known conditions other than 
paralysis that are known to influence bone 
metabolism including: metabolic disorders, oral 
glucocorticoid use for ≥3 months, malignancy, 
known liver or malabsorption condition 
• Weight > 270 lbs (limit for bone density 
machine) 
• Contraindications to pQCT testing (e.g. bilateral 




For the second study, “Intermittent whole body vibration and passive standing for treatment 
of sublesional osteoporosis after spinal cord injury pilot study phase II: safety and efficacy 
assessment”, the inclusion and exclusion criteria were more rigorous. The inclusion criteria were 
intended to select a homogenous sample of adult men with chronic motor complete paraplegia. 
The exclusion criteria were intended to identify potential subjects for whom exposure to 
intermittent whole body vibration would be unsafe or whom passive standing would be unsafe. 
Inclusion and exclusion criteria are outlined below: 
 
Table 4: Participant Inclusion and Exclusion Criteria for Whole Body Vibration Study 
Inclusion Exclusion 
• Men 
• Motor complete paraplegia (T2 to T10, 
AIS A & B) 
• 20-60 yrs of age 
• Traumatic SCI 
• Chronic (>2 yrs) SCI 
 
• Failed PRP 
• >250lbs (113kg) and >6ft (183cm) 
• Unable to complete PRP in 5 sessions 
• History or development of: uncontrolled 
autonomic dysreflexia, untreated orthostatic 
hypotension, seizure disorder, migraine 
headaches, rheumatoid arthritis, kidney stones, 
arrhythmias, valvular heart disease, non-union 
fragility fracture, dislocated hip, cochlear 
implants, deep vein thrombosis, 
spondylolisthesis, joint implant, diabetes, 
gallstones, pacemaker, cancer, lower extremity 
pressure ulcer 
• Conditions of: bilateral heterotopic ossification 
of the hip or knee region, plantar flexor 
contractures of >.20°, combined hip and knee 
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flexion contracture >30° 
• Use of oral bisphosphonate 
• Concurrent participation in another intervention 
study or program which would confound 
interpretation of the study results 
• Cancer or radiotherapy 
3.2.2: Screening 
The screening protocol for the bone quality study consisted of determining the participants’ 
eligibility and providing them a detailed description of the study.  
Due to the potential safety hazard of the WBV intervention, this study had a rigorous 
screening protocol. The screening visit included collecting written informed consent, a medical 
history form, a physical examination, serum Vitamin D and hemoglobin screening, an ultrasound 
of the kidneys and bladder to ensure the participant did not have kidney stones or 
hydronephrosis, an x-ray of the spine to ensure the participant did not have loose or broken 
hardware, and [if necessary] a postural retraining program (PRP). A physician who was part of 
the research team evaluated the participants’ medical history to determine if there was any reason 
they should not participate. 
Individuals with SCI experience autonomic nervous system impairments following injury, 
including difficulty with blood pressure regulation. Orthostatic hypotension can result when 
changing body positions, such as from sitting to standing. Orthostatic hypotension is defined as a 
drop in systolic blood pressure below 70mmHg, diastolic blood pressure below 40mmHg, or 
heart rate below 50 beats per minute. Therefore, participants with SCI who did not stand on a 
regular basis were asked to complete a PRP prior to commencement of the study to ensure safe 
standing during the study. Postural retraining is a means of using a tilt table to trigger 
baroreceptors to accommodate for changes in the participant’s position (sit to stand). This tool 
has been previously used to identify participants who were unsafe to engage in passive standing, 
and successful completion of PRP was predictive of safe standing (306). 
The PRP was deemed complete when the participant could stand in a tilt table for 30 minutes 
at a near erect posture without symptoms of orthostatic hypotension or a significant drop in heart 
rate or blood pressure from their seated posture. To date, the side effects from previous studies 
on standing in the SCI population at Lyndhurst include rare occurrences of orthostatic 
hypotension, three cases of syncope, one case of deep vein thrombosis, ten cases of pressure 
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sores, and five reports of pain. The PRP helps the participants body get used to being upright 
before using the standing device. Up to five training sessions over a two-week period were 
dedicated to getting the participant used to standing again. If a participant was not able to 
become accustomed to standing after the two-week period, the participant was excluded from 
further participation so as to minimize risks associated with standing during the pilot intervention 
period. In previous standing studies conducted at Lyndhurst Center, only 3 of 60 participants 
failed the postural re-training program. 
3.2.3: Participants 
A sample of 16 individuals (13 men, 3 women) with chronic SCI participated in this study, 
and the data were obtained at Lyndhurst Center, Toronto Rehabilitation Institute as well as at 
McMaster University. Informed consent was obtained from each of the participants within their 
respective studies (Appendix A and Appendix B). When exploring the relationship between 
muscle and bone, 41 individuals (32 men, 9 women) with chronic SCI participated, and the data 
were obtained at McMaster University. Informed consent was obtained prior to participation.  
3.3: Methodology 
3.3.1: Primary Outcome Measures 
Lean tissue, adipose tissue, and bone tissue composition was measured via DXA and pQCT, 
in addition to surrogates of body adiposity (BMI and WC). Lean tissue was measured via muscle 
CSA (mm2) and muscle density (mg/cm3) using pQCT. Adipose tissue was measured via BMI 
(kg/m2) and WC (cm) using a floor scale and tape measure, and whole body % fat using DXA. 
Bone tissue was measured via hip, distal femur, and proximal tibia aBMD (g/cm2) using DXA; 
cortical thickness (mm), cortical bone CSA (mm2), total vBMD (mg/cm3), and total BMC 
(mm/mg) at the 1/3 proximal tibia using pQCT; and trabecular vBMD (mg/cm3), total vBMD 
(mg/cm3), and total BMC (mg/mm) at the distal tibia using pQCT. 
3.3.1.1: Lean Tissue 
Muscle CSA (mm2) and muscle density (mg/cm3) were obtained from pQCT scans of the 1/3 
proximal tibia. Images were acquired using a Stratec XCT 2000 scanner (Stratec Medizintechnik, 
Germany) (picture within Appendix B); a translate-rotate, small-bore computed tomography 
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scanner that acquires a transaxial image from 145 projection scans. Bony landmarks at the knee 
joint and medial malleolus were palpated and a measuring tape was used to measure the distance 
between them. The 1/3 proximal tibia site was 66% of tibia length, measuring from distal 
landmark. Sixty-six percent of the tibia length was chosen because in this region the muscle has 
the highest circumference and cross-sectional area (307, 308). The participants’ lower leg was 
placed into the scanner. The scanner obtained slice widths of 2.2mm, and a voxel size of 0.5mm. 
A slice width of 2.2mm was chosen because it has been reported that accurate measures of 
vBMD obtained from pQCT scans can be obtained at slice widths of >2mm (309).  
To analyze a pQCT scan for muscle CSA, the Stratec XCT 2000 software was used. Contour 
mode is used to find the edge using a contour detection algorithm. It will find pixels with similar 
values along the boundary of a tissue using the threshold that is set. When performing the first 
step in the muscle CSA analysis, the contour mode is used to detect the boundary between skin 
and air. Peel mode is used to separate between two types of tissues, using a threshold. Contour 
mode 1, peel mode 2, and -100/40mg/mm3 thresholding was used to separate muscle/bone/skin 
pixels from pixels containing adipose tissue. Contour mode 1 and 710mg/mm3 threshold was 
used to determine the pixels belonging to bone, and finally contour mode 4 and -
100/2000mg/mm3 was used to determine the pixels belonging to skin. The bone and skin areas 
were then subtracted from the muscle/bone/skin area to obtain total muscle CSA (mm2). 
To analyze a pQCT scan for muscle density, the Stratec XCT 2000 software was used. The 
first step was to remove the skin and SAT using a contour mode 3, peel mode 1, and threshold of 
40mg/mm3. Total muscle & bone area as well as total muscle & bone density were the outcomes; 
total muscle & bone mass was subsequently determined. The second step was to remove the 
skin, SAT, and muscle using a contour mode 1, peel mode 2, and threshold of 280mg/mm3. Total 
bone area and total bone density were the outcomes; total bone mass was subsequently 
determined. Muscle mass and muscle area were then calculated by subtracting the total bone 
mass from the total muscle & bone mass, and the total bone area from the total muscle & bone 
area, respectively. Finally, muscle density was determined by dividing the muscle mass by the 
muscle area, and reported as mg/cm3.  
3.3.1.2: Adipose tissue 
BMI (kg/m2) and WC (cm) were measured as surrogates of body adiposity. For BMI, 
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participants were weighed using a scale (BMH Medical Inc., model 6059) that was attached to a 
ceiling lift. As the participant was being transferred from their wheelchair to the DXA table, their 
weight was recorded in pounds, and subsequently converted to the nearest 0.1 kg. If the 
participant did not use the ceiling lift, they were weighed in their wheelchair to the nearest 0.1 kg 
on a floor scale at Lyndhurst Center (Seiko Scale, Stathmos, type 513-417). Once they 
transferred from their wheelchair for other measurements, their wheelchair weight was measured 
and subtracted from the total weight to determine body weight. Length measurements were made 
using a flexible non-elastic Gulick II tape measure (Country Technology Inc, Gay Mills, WI) to 
the nearest 0.001 m. All measurements were taken on the right side of the body from the heel to 
the crown of the head while the participant lay in a supine position. The participant’s feet were 
stretched into dorsiflexion where possible. Length measures were taken in segments from the 
heel to crown if participants had contractures that prevented the straightening of their legs. BMI 
was determined by dividing the participants body weight (kg) by their length (m) squared.  
The measurement for WC was taken after normal expiration immediately below the lowest 
rib in a supine position (53, 202) with the same tape measure as used for participant length 
(Gulick II).  For each WC measurement, the tape measure was placed directly on the skin with 
the participants’ arms by their sides. Each measurement was taken to the nearest 0.1 cm. 
Whole body % fat was measured with a Hologic DXA device (Hologic Inc., Hologic QDR-
4500A; MA, USA) (picture within Appendix B), using standard protocols provided by the 
manufacturer. Whole body scans were analyzed using commercially available software from 
Hologic. The precision and accuracy of DXA for soft tissue has been reported to be 99% and 
<1% error (310). The participant was positioned supine on the scanning table, and scanning was 
performed in a rectilinear fashion, taking approximately 15 minutes. For the whole body 
scanning required for % body fat measurement, it was essential that all parts of the body 
(including the arms) were included in the scan field. 
3.3.1.3: Bone Tissue 
Areal BMD of the hip, distal femur, and proximal tibia were measured with DXA. The hip 
scan was obtained using a standard protocol provided by the manufacturer. Distal femur and 
proximal tibia scans were acquired and analyzed using a lower extremity positioning device and 
protocol whose reliability and accuracy have been previously determined (56). The participant 
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was positioned supine on the scanning table, and scanning was performed in a rectilinear fashion, 
taking approximately 15 minutes per site examined. Intra-class correlation coefficients for 
repeated distal femur and proximal tibia BMD measures are 0.99 and 0.97, respectively. The 
accuracy of DXA for aBMD measurement is 3%-8% (311-313), and the precision of DXA 
differs depending on the anatomical site measured. The precision of DXA is better among 
individuals with normal BMD than among osteoporotic persons. For the regional scanning of the 
hip, distal femur, and proximal tibia, it was important to position the body for the specific site 
being measured, as different leg positions can cause errors in BMD measurement. Trained 
technologists in the Bone Density Lab at Lyndhurst Centre performed the scans. The site is 
equipped with a lift for transferring patients onto the scan bed.  
Cortical bone CSA (mm2), cortical thickness (mm), total vBMD (mg/cm3), and total BMC 
(mg/mm) at the 1/3 proximal tibia; and trabecular CSA (mm2), trabecular vBMD (mg/cm3), total 
vBMD (mg/cm3), and total BMC (mg/mm) at the distal tibia were obtained from pQCT scans of 
the tibia. Just as for the lean tissue images from pQCT, the bone tissue images were acquired 
using a Stratec XCT 2000 scanner. Bony landmarks at the knee joint and medial malleolus were 
palpated and a measuring tape was used to measure the distance between them. The 1/3 proximal 
tibia site was 66% of tibia length, measuring from the distal landmark, and the distal tibia site 
was 4% of tibia length, measuring from the distal landmark. The participants’ lower leg was 
placed through the scanner. The scanner obtained slice widths of 2.2mm at both the 1/3 proximal 
tibia and distal tibia sites, and a voxel size of 0.5mm and 0.2mm at the 1/3 proximal tibia and 
distal tibia, respectively.  
To analyze the pQCT scans for bone parameters, the Stratec XCT 2000 software was used, 
and different contour modes, peel modes, and thresholds were used at the 1/3 proximal tibia and 
distal tibia sites. At the 1/3 proximal tibia site (66%), total and cortical parameters were analyzed 
using contour mode 1 and 280mg/mm3 threshold. Contour mode 1 is the default analysis mode; it 
is threshold driven and used to separate soft tissue from the outer edge of bone. Any voxel with a 
density below the set threshold is eliminated, and 280mg/mm3 is considered to be the threshold 
for soft tissue (adipose tissue and lean tissue). At the distal tibia site (4%), total and trabecular 
parameters were analyzed using contour mode 3, peel mode 2, and 130/400mg/mm3 outer 
threshold/inner threshold values. Contour mode 3 employs a contour detection algorithm to find 
the bone edge; it has user-defined thresholds and in the present study 130mg/mm3 was chosen. 
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Peel mode 2 uses inner thresholds to separate the total area into trabecular and subcortical bone, 
and provides information on trabecular bone parameters; it uses thresholds based on density and 
in the present study 400mg/mm3 was used (38).  
3.3.2: Summary of Primary Outcome Measures  
Table 5 provides a summary of the lean tissue, adipose tissue, and bone tissue outcomes used 
in this study. In addition, lean tissue normative values (110) as well as adipose tissue (13, 32, 33, 
221, 229, 230) and bone tissue (34, 35, 271) SCI-specific and able-bodied definitions for obesity, 






Table 5: Summary of Normative Values and Definitions for Body Composition Assessment 
Able-Bodied Normative Values / Definitions of Obesity and 
Osteoporosis Outcomes 
Men Women 
Spinal Cord Injury-Specific 
Definitions 
Muscle Density (mg/cm3) 
(pQCT) 
Normative Value: 
75.2 mg/cm3 (110) 
Normative Value: 
72.4 mg/cm3 (110) N/A 
Muscle CSA at Calf (mm2) 
(pQCT) Normative Value: 7019.6±1331 mm
2 N/A 
 
Body Mass Index (kg/m2) 




Obese I: 30-34.9 
Obese II: 35-39.9 
Obese III: ≥40 (221) 
High risk for obesity and obesity-related 
diseases: 
>22 kg/m2 (32) 
>25 kg/m2 (13, 33) 
 (No universally accepted value) 
Waist Circumference (cm)  
(tape measure) Obese: >102 cm (>40 in) (229) Obese: >88 cm (>35 in) (229) N/A 





































Premenopausal women and men <50 yrs; can be used to define osteoporosis at the 
hip, distal femur, and proximal tibia (271): 
Below expected range: Z-score: <-2.0 
Within expected range: Z-score: >-2.0 
Fracture threshold distal femur: 
0.78g/cm2 (34) 
Fracture breakpoint distal femur: 
0.49g/cm2 (34) 
Trabecular vBMD (mg/cm3) 
 (pQCT) N/A N/A 




3.3.3: Secondary Outcome Measures 
3.3.3.1: Muscle-Bone Unit 
The relationship between muscle and bone among the present cohort of individuals with 
chronic SCI, as well as an additional 29 individuals from previous studies out of Lyndhurst 
Center, Toronto Rehabilitation Institute, was determined by correlating an index of muscle 
strength with indices of bone strength. Muscle CSA has been shown to be a good index of 
muscle strength (3, 40). It has been suggested that a reduction in all of cortical thickness, cortical 
bone CSA, and total BMC at the 1/3 proximal tibia (66%), and total vBMD, trabecular vBMD, 
and total BMC at the distal tibia (4%) occurs following SCI. All of the measures are valid and 
interpretable. 
3.3.3.2: Adipose Tissue and Bone 
The relationship between obesity and osteoporosis among the present cohort of individuals 
with chronic SCI was determined by correlating indices of obesity with indices of SLOP. The 
indices of obesity [WC, BMI, and whole body % fat] were chosen because they are all used to 
define obesity and identify people at high risk for obesity-related diseases (32, 53, 197-201, 221). 
The first index of SLOP [distal femur aBMD, g/cm2] was chosen because it is the most frequent 
site of fracture after SCI (22, 72, 73). The distal femur is a more precise and reliable measure of 
aBMD when using DXA than the proximal tibia (74). The second index of SLOP [distal tibia 
trabecular vBMD] was chosen because accelerated bone loss and fractures often manifest at 
skeletal sites with a higher proportion of trabecular bone, and trabecular vBMD has been shown 
to be associated with fractures in cross-sectional studies (35). Each of the aforementioned 
measures is valid and interpretable. 
3.4: Data Analysis 
Descriptive statistics were used to describe the participant’s demographic and impairment 
characteristics. Lean tissue, adipose tissue, and bone tissue composition were presented as 
average±standard deviation for continuous variable and count (%) for categorical variables. The 
number of individuals with chronic SCI that had values above and below able-bodied normative 
values for muscle CSA and muscle density listed in Table 5 were reported. In addition, the 
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number of individuals with chronic SCI who were obese, had SLOP, and/or who were at risk of 
fracture using SCI-specific and able-bodied definitions listed in Table 5 were reported.  
Linear regression analysis was performed to determine the relationship between % body fat 
and BMI. The line of best fit was used to approximate the % body fat associated with a BMI of 
22 kg/m2 (32), 25 kg/m2 (13, 33), and 30 kg/m2 (221). 
Participants were characterized based on 5 risk factors of sex (female), age (≥60 years), DOI 
(≥10 years), NLI (tetraplegia), and AIS (motor complete). A BMI >22 kg/m2 defined the 
presence of obesity, and a distal femur Z-score of <-2.0 defined the presence of SLOP. The 
number of participants correctly and incorrectly identified to have obesity and SLOP based on 
the presence of ≥2 or ≥3 risk factors was determined.  
Pearson Correlations were used to assess the associations between an index of muscle 
strength (muscle CSA) and indices of bone strength (cortical bone CSA, cortical thickness, total 
vBMD, and total BMC at the 1/3 proximal tibia [66%], and trabecular CSA, trabecular vBMD, 
total vBMD, and total BMC at the distal tibia [4%]). The strength of the relationship was 
determined based on the correlation values and interpretation in Table 6 (314). The data was 
evaluated for normality. 
Pearson Correlations were used to assess the associations between indices of obesity (WC, 
BMI, and whole body % fat) and indices of SLOP (distal femur aBMD, and distal tibia 
volumetric vBMD). The strength of the relationship was determined based on the correlation 
values and interpretation in Table 6 (314). For all analyses, significance was accepted at the 
p<0.05 level. All statistical analyses were performed using SAS 9.1.3 software. 
 
Table 6: Interpreting Pearson Correlation Values 
Correlation Value Interpretation 
≤0.29 Very weak 
0.30 to 0.49 Weak 
0.50 to 0.69 Moderate 
0.70 to 0.89 Strong 






The cohort consisted of 16 participants, 13 men (81%) and 3 women (19%). Data from 14 
participants (11 men, 3 women) was utilized from the Bone Quality Study, and data from 2 
participants (2 men) was utilized from the WBV Study. One hundred and twenty-nine 
individuals with chronic SCI were contacted for the Bone Quality Study, 16 were screened, and 
14 were enrolled. Twenty-one individuals were contacted for the WBV study, 4 were screened, 
and 2 were enrolled. A flow chart of the subjects contacted, screened, and enrolled can be found 




















Figure 1: Subject Screening and Recruitment Flow Chart  
 
Subjects Screened 
N = 16 (Bone Quality) 
N = 4 (WBV) 
Subjects Enrolled 
N = 14 (Bone Quality) 














N = 1 
NLI T2-T12 
(Paraplegic) 








N = 129 (Bone Quality) 




All participants experienced a traumatic SCI more than 2 years ago from a fall (n=8; 50%), 
motor vehicle accident (n=6; 38%), assault (n=1; 6%), or gunshot wound (n=1; 6%). The NLI 
ranged from C3-T12, with 9 AIS A-B and 7 AIS A-D. Average±standard deviation (range) for 
age was reported as 51.12±12.37 (32 – 76) years, DOI 16.5±7.87 (6 – 29) years, height 
1.76±0.09 (1.65 – 1.93) m, and weight 84.41±22.0 (53.1 – 137.44) kg. Demographic (age, sex, 
height, weight) and impairment characteristics (NLI, AIS, and DOI) of each participant can be 
found in Table 7. 
 
Table 7: Demographic and Impairment Characteristics 




(kg) NLI AIS DOI 
1 M 51 1.75 88.90 C6 D 6 
2 F 72 1.65 72.57 T6 D 28 
3 M 44 1.80 77.11 C6 D 25 
4 M 54 1.63 65.77 T12 A 12 
5 M 76 1.88 111.13 C4 D 11 
6 F 52 1.73 74.62 T11 A 22 
7 M 44 1.93 101.60 C4 C 19 
8 M 67 1.86 99.79 T12 A 13 
9 M 34 1.75 58.06 T6-7 A 6 
10 M 53 1.73 82.10 T10 A 8 
11 M 54 1.80 68.04 C3-4 C 29 
12 M 40 1.83 137.44 T6 A 20 
13 M 43 1.80 82.10 C4 A 12 
14 M 54 1.68 105.7 T9 D 8 
15 F 32 1.65 53.1 T4 A 23 
16 M 48 1.73 72.6 T12 B 22 
        
AVERAGE ---- 51.12±12.37 1.76±0.09 84.41±22.00 ---- ---- 16.50±7.87 
NLI = Neurological Level of Injury; AIS = American Spinal Injury Association Impairment Scale; DOI = Duration 
Of Injury 
 
When exploring the relationship between muscle and bone, data from 29 additional 
individuals with chronic SCI (DOI >2 years) were included. Forty-one individuals (32 men, 9 
women) participated. The NLI ranged from C2-T12, with 13 AIS A-B, and 28 AIS C-D. 
Average±standard deviation age was 48.7±13.36 years, and DOI 14.22±10.4 years. A summary 
of the average±standard for demographic (age, sex) and impairment characteristics (NLI, AIS, 




Table 8: Demographic and Impairment Characteristics of Larger Cohort 
N 41 
Ratio men:women 4:1 (32 men, 9 women) 
*Age (years) 48.70±13.36 
*DOI 14.22±10.40 
NLI C2-T12 
AIS 13 A-B; 28 C-D 
*Reported as mean ± SD; N = Sample Size; DOI = Duration of Injury; NLI = Neurological Level of Injury; AIS = 
American Spinal Injury Association Impairment Scale. 
 
4.1.1: Sample Size for Body Composition Measures  
4.1.1.1: Lean Tissue  
Values from pQCT were obtained from 12 participants, as 4 participants were not scanned 
prior to September 2009. Average±standard deviation was found to be 4914.2±2577.173 mm2 
for muscle CSA at the 1/3 proximal tibia (66%). Analysis for muscle density from the pQCT 
scans were completed for only 8 individuals, as the algorithm used in the Stratec XCT-2000 
software was unable to consistently find the contours necessary to determine muscle density 
among 4 of the participants; average±standard deviation was found to be 53.29±15.54 mg/cm3 
for muscle density at the 1/3 proximal tibia (66%) among the 8 individuals. 
4.1.1.2: Adipose Tissue  
Surrogates of body adiposity (WC, BMI) were obtained from all 16 participants, 
average±standard deviation was found to be 99.08±17.85 cm for WC, and 27.00±5.93 kg/m2 for 
BMI. Values from DXA for % body fat (31.46±8.95 %) were obtained from 15 participants as 
one male was >270 lbs (the limit for the DXA scanner). 
4.1.1.3: Bone Tissue  
Values proximal tibia aBMD (0.45±0.14 g/cm2) were obtained from 15 participants as one 
male was >270 lbs (the limit for the DXA scanner). Values from DXA for hip aBMD (0.71±0.16 
g/cm2) were obtained from 14 participants as one participant had metal in both hips, precluding 
accurate assessment. DXA values for distal femur aBMD (0.56±0.22 g/cm2) were obtained from 
14 participants, as one participant had metal plates in both knees. Values from pQCT were 
obtained from 12 participants, as 4 participants were not scanned prior to September 2009. 
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Average±standard deviation was found to be 3.57±1.06 mm2 for cortical thickness at the 1/3 
proximal tibia (66%), 538.23±105.16 mg/cm3 for total vBMD at the 1/3 proximal tibia (66%), 
129.22±43.62 mg/cm3 for trabecular vBMD at the distal tibia (4%), and 170.57±56.90 mg/cm3 
for total vBMD at the distal tibia (4%). A summary of the lean tissue, adipose tissue, and bone 
tissue body composition values are presented in Table 9. All data was normally distributed. 
 
Table 9: Body Composition after Spinal Cord Injury  
Outcome Able-Bodied Normative Value 
Cohort of SCI 
Average±Standard Deviation 
Muscle CSA (mm2) (n=12) 7019.6±1331 4914.2±2577.173 
Muscle Density (mg/cm3) (n=8) 75.2 (men) 72.4 (women) 53.29±15.54 
   
WC (cm) (n=16) <102 (men) <88 (women) 99.08±17.85 
BMI (kg/m2) (n=16) 18.5-24.9 27.00±5.93 
 Body Fat (%) (n=15) 8-19% (men) 21-32% (women) 31.46±8.95 
   
Hip aBMD (g/cm2) (n=14) Z-score >-2 50% below Z-score -2; 0.71±0.16 
Distal Femur aBMD (g/cm2) (n=14) Z-score >-2 100% below Z-score -2; 0.56±0.22 
Proximal Tibia aBMD (g/cm2) (n=15) Z-score >-2 80% below Z-score -2; 0.45±0.14 
Cortical Thickness (66%) (mm2) (n=12) ---- 3.57±1.06 
Total vBMD (66%) (mg/cm3) (n=12) ---- 538.23±105.16 
Trabecular vBMD (4%) (mg/cm3) (n=12) ---- 129.22±43.62 
Total vBMD (4%) (mg/cm3) (n=12) ---- 170.57±56.90 
WC = Waist Circumference; BMI = Body Mass Index; CSA = Cross Sectional Area; aBMD = areal Bone Mineral 
Density; vBMD = volumetric Bone Mineral Density; BMC = Bone Mineral Content 
 
4.2: Lean Tissue after Spinal Cord Injury 
The number of individuals with SCI who were above and below able-bodied normative 
values for muscle CSA and muscle density are reported in Table 10, categorized by 
completeness of injury. It was found that 67% of individuals with SCI had muscle CSA values 
below the able-bodied norm, and 100% of individuals with SCI had muscle density values below 
the able-bodied norm. Among individuals with complete (AIS A-B) SCI, 83% and 100% had 
muscle CSA (n=6) and muscle density (n=3) values, respectively, below able-bodied normative 
 
 56 
values. Among those with incomplete (AIS C-D) SCI, 50% and 100% had muscle CSA (n=6) 
and muscle density (n=5) values, respectively, below able-bodied normative values. 
 
Table 10: Number of Participants with SCI who had Muscle CSA and Muscle Density Values 
Above and Below Able-Bodied Norms  
Muscle CSA  
<7019.6±1331 mm2 
Muscle Density 
<75.2 mg/cm3 (Men) 
<72.4 mg/cm3 (Women) 
 
+ - + - 
All 8 4 8 0 
 
AIS A-B 5 1 3 0 
AIS C-D 3 3 5 0 
+ = At Risk (below normative value); - = Not At Risk (above normative value); CSA = Cross Sectional Area 
 
4.3: Adipose Tissue after Spinal Cord Injury 
The number of individuals with SCI who were obese using able-bodied or SCI-specific 
definitions are reported in Table 11 and Table 12. When using the able-bodied definition of BMI 
>30 kg/m2, <20% of the cohort was obese, whereas >60% and >80% of individuals were obese 
using SCI-specific definitions of BMI >25 kg/m2 or >22 kg/m2, respectively. When able-bodied 
definitions of WC and % body fat were employed, 50% and 87% of individuals with chronic SCI 
in the present study were obese, respectively. 
To elaborate, a larger proportion of individuals with incomplete SCI were obese (71% and 
86%) when compared to individuals with motor complete SCI (56% and 78%) using BMI >25 
kg/m2 and >22 kg/m2, respectively. 
 




WC >102cm (Men) 
WC >88cm (Women) 
Obesity 
BMI >30 kg/m2 
Obesity 
BMI >25 kg/m2 
Obesity 
BMI >22 kg/m2 
 + - + - + - + - 
All 8 8 3 13 10 6 13 3 
         
AIS A-B 4 5 1 8 5 4 7 2 
AIS C-D 4 3 2 5 5 2 6 1 







Table 12: Number of Participants with SCI Classified as Obese Based on % Body Fat from 
DXA (Categorized by Sex, Age, and Completeness of Injury) 
 Age Definition + - 
20-39 Normal: <20% 
Overweight/Obese: ≥21% 
0 1 
40-59 Normal: <22% 
Overweight/Obese: ≥23% 
9 0 Men 
60-79 Normal: <24% 
Overweight/Obese: ≥25% 
2 0 
20-39 Normal: <32% 
Overweight/Obese: ≥33% 
0 1 
40-59 Normal: <34% 
Overweight/Obese: ≥35% 
1 0 Women 
60-79 Normal: <37% 
Overweight/Obese: ≥38% 
1 0 
All 13 2 
 
AIS A-B 6 2 
AIS C-D 7 0 
+ = Obese; - = Not Obese 
 
 
When % body fat was plotted against BMI for all 15 individuals in the present study (Figure 
2), it was found that a BMI of 22 kg/m2 corresponded with a % body fat of ~29%, a BMI of 25 
kg/m2 corresponded with a % body fat of ~31%, and a BMI of 30 kg/m2 corresponded with a % 
body fat of ~34%. 
 
 





4.4: Bone Tissue after Spinal Cord Injury 
The number of individuals with SCI who had SLOP or who were at risk of fracture using 
SCI-specific definitions, respectively, are reported in Table 13 and Table 14. It was found that 
50%, 100% and 80% of individuals with chronic SCI in the present study had SLOP based on 
able-bodied definitions of a Z-score <-2.0 at the hip, distal femur, and proximal tibia, 
respectively. The distal femur and proximal tibia are skeletal sites most common to fracture after 
SCI. A larger proportion of individuals with motor complete SCI had SLOP (86%, 100%, and 
100%) when compared to individuals with incomplete SCI (14%, 100%, and 57%) using a Z-
score of <-2.0 at the hip, distal femur, and proximal tibia, respectively. 
 
Table 13: Number of Participants with SCI Classified as having SLOP Based on ISCD Z-scores 
from DXA 
SLOP 











+ - + - + - 
All 7 7 14 0 12 3 
       
AIS A-B 6 1 7 0 8 0 
AIS C-D 1 6 7 0 4 3 
ISCD = International Society of Clinical Densitometry; + = Osteoporotic; - = Not Osteoporotic; AIS = American 
Spinal Injury Association Impairment Scale; aBMD = areal Bone Mineral Density 
 
Table 14: Number of Participants with SCI Classified as at Risk of Fracture Based on SCI-
Specific Fracture Thresholds from DXA and pQCT  
 
Fracture Threshold 






aBMD <0.49 g/cm2 
Fracture Threshold 
at Distal Tibia 
vBMD  
<70 mg/cm3 
 + - + - + - 
All 11 3 7 7 1 11 
       
AIS A-B 7 0 7 0 1 5 
AIS C-D 4 3 0 7 0 6 
+ = Osteoporotic; - = Not Osteoporotic; AIS = American Spinal Injury Association Impairment Scale; aBMD = 
areal Bone Mineral Density; vBMD = volumetric Bone Mineral Density 
 
It was found that 79% and 50% of individuals with chronic SCI in the present study were at 
risk for fracture based on SCI-specific definitions of a fracture threshold at the distal femur <0.78 
g/cm2 and a fracture breakpoint at the distal femur <0.49 g/cm2, respectively. Further, 1% of 
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individuals with chronic SCI were at risk for fracture based on the SCI-specific definition of a 
fracture threshold at the distal tibia <70 mg/cm3. A larger proportion of individuals with motor 
complete SCI were at risk of fracture (100%, 100%, and 17%) when compared to individuals 
with incomplete SCI (57%, 0%, and 0%) using a fracture threshold of <0.78 g/cm2 at the distal 
femur, a fracture breakpoint of <0.49 g/cm2 at the distal femur, and a fracture threshold of <70 
mg/cm3 at the distal tibia, respectively. 
4.5: Identifying Risk Factors for Obesity and Sublesional Osteoporosis 
Five risk factors for obesity and SLOP after SCI include sex (female), age (≥60 years), DOI 
(≥10 years), NLI (tetraplegia), and AIS (motor complete). The number of participants with each 
risk factor is presented as a histogram in Figure 3. The number of risk factors that each 
participant possessed was matched to the presence of obesity and SLOP. When using ≥3 risk 
factors to identify those at risk of obesity (BMI >22 kg/m2) or SLOP (distal femur Z-score <-2), 
10 individuals in the present cohort were undetected. When using ≥2 risk factors to identify those 
at risk of obesity or SLOP, 4 individuals were undetected with no false positives. Twelve 
participants in the present cohort were at high risk of being obese and/or having SLOP when 
utilizing the ≥2 risk factors taxonomy. 
Among the individuals defined as obese in the present cohort (81% with BMI >22 kg/m2), 
77% had ≥2 risk factors. Among the individuals defined as having SLOP in the present cohort 
(100% with Z-score <-2.0), 71% had ≥2 risk factors. Among the individuals who were both 





Figure 3: Number of Participants with Each Risk Factor 
 
4.6: Muscle-Bone Unit after Spinal Cord Injury 
When exploring the correlations between lean tissue and bone tissue, data from 41 
individuals with chronic SCI were included. The muscle and bone characteristics for this cohort 
can be found in Table 15.  
 
Table 15: Muscle and Bone Characteristics from Larger Cohort 
Outcome (n=41) Average ±  Standard Deviation 
Muscle CSA (mm2) 4863.52±2080.40 
  
Cortical Bone CSA 66% (mm2) 288.35±80.04 
Cortical Thickness 66% (mm) 3.48±0.91 
Total vBMD 66% (mg/cm3) 553.49±94.23 
Total BMC 66% (mg/mm) 391.26±90.21 
Trabecular Bone CSA 4% (mm2) 1109.65±200.70 
Trabecular vBMD 4% (mg/cm3) 138.97±55.30 
Total vBMD 4% (mg/cm3) 186.74±66.64 
Total BMC 4% (mg/mm) 230.03±85.72 
CSA = Cross Sectional Area; vBMD = volumetric Bone Mineral Density; BMC = Bone Mineral Content 
 
Weak correlations were found between muscle CSA and cortical bone CSA (r=0.48, 
p<0.001), cortical thickness (r=0.42, p=0.005), and total BMC (r=0.46, p=0.002) at the 1/3 
proximal tibia (66%). These correlations are shown in graph form in Figure 4, Figure 5, and 












Figure 6: Total BMC at 66% (mg/mm) vs. Muscle CSA (mm2); r=0.46; p=0.002 
 
Moderate correlations were found between muscle CSA and trabecular vBMD (r=0.55, 
p<0.001), total vBMD (r=0.54, p<0.001), and total BMC (r=0.57, p<0.001) at the distal tibia 












Figure 9: Total BMC at the 4% (mg/mm) vs. Muscle CSA (mm2); r=0.57; p<0.001 
 
No significant relationship was found between muscle CSA and total vBMD (r=0.29, 
p=0.06) at the 1/3 proximal tibia (66%), or between muscle CSA and trabecular CSA r=0.0195; 
p=0.903) at the distal tibia (4%). These correlations are shown in graph form in Figure 10 and 








Figure 11: Trabecular Bone CSA at 4% (mm2) vs. Muscle CSA (mm2); r=0.02; p=0.90 
 
4.7: Adipose Tissue and Bone after Spinal Cord Injury 
When exploring the correlations between adipose tissue and distal femur aBMD, data from 
14 individuals with chronic SCI was included. No significant correlations were found between 
distal femur aBMD and WC (r=0.34, p=0.21), BMI (r=0.39, p=0.16), or % body fat (r=0.03, 
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Figure 12: WC (cm) vs. Distal Femur aBMD (g/cm2); r=0.34; p=0.21 
 
 






Figure 14: Body Fat (%) vs. Distal Femur aBMD (g/cm2); r=0.03; p=0.91 
 
When exploring the correlations between adipose tissue and distal tibia trabecular vBMD, 
data from 12 individuals with chronic SCI were included. No significant correlations were found 
between distal tibia trabecular vBMD and WC (r=0), BMI (r=0), and % body fat (r=0). These 
correlations are shown in Figure 15, Figure 16, and Figure 17, respectively. One individual had a 
% body fat that is not characteristic of an individual with chronic SCI; his % body fat was lower 
than 2 standard deviations below the mean at 12%. When this outlier was removed, a Pearson 
Correlation of r=0.56 (p=0.09) was found for the relationship between distal tibia trabecular 

























Our primary findings were: 
1. There was a prevalence of muscle loss, adipose tissue gain, and bone tissue loss among 
the cohort of individuals with chronic SCI in this study.  
2. There was an underrepresentation of obesity among the present cohort when the able-
bodied definition of BMI >30 kg/m2 was utilized; it appeared as though the SCI-
specific definitions of BMI >25 kg/m2 or >22 kg/m2 were more sensitive in identifying 
those who were obese. 
3. The ISCD Z-scores at the distal femur identified 100% of the individuals in the present 
cohort as having SLOP, whereas the fracture threshold at the distal femur identified 
>75% of the individuals in the present cohort as being at risk of fracture. 
4. The presence of ≥2 risk factors (female, ≥60 years of age, DOI ≥10 years, tetraplegia, 
motor complete) identified individuals with SCI in need of body composition screening 
to subsequently detect those who were obese or who had SLOP. Body composition 
screening should include % body fat and SCI-specific BMI and WC measures to detect 
obesity, and distal femur Z-score and fracture threshold to detect SLOP and fracture 
risk, respectively. 
5. Weak to moderate correlations were found between muscle CSA and indices of bone 
strength, supporting the theory of a muscle-bone unit. 
6. No correlations were found between indices of obesity and indices of SLOP. However, 
when one outlier was removed, a trend towards significance was found between distal 
tibia trabecular vBMD and % body fat.  
 
The ratio of men:women at 4:1 in the present study is representative of the SCI population, 
and there was a fairly balanced proportion of individuals in each category of motor complete 
(AIS A-B) (n=9) and incomplete (AIS C-D) (n=7) SCI.  
5.1: Lean Tissue after Spinal Cord Injury 
Two thirds of individuals with SCI had muscle CSA values below able-bodied normative 
values, consistent with previous reports of drastic reductions in muscle CSA following SCI (1, 
2). Individuals with SCI in our study had 35% less muscle CSA than the able-bodied norm, 
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whereas others have reported a 24-31% lower muscle CSA among persons with incomplete SCI 
when compared to controls (98). When taking the completeness of injury into account, 
individuals with incomplete SCI in the present cohort had 6% less muscle CSA than the able-
bodied normative values, and individuals with motor complete SCI had 75% less muscle CSA 
than the able-bodied normative values. In both of these aforementioned studies, three quarters of 
the participants were AIS D, capable of ambulation in their homes and in the community, 
perhaps contributing to preservation of muscle CSA. The difference in muscle CSA [6% vs. 24-
31%] among individuals with incomplete SCI may be due to DOI [16.5±7.87 years vs. 13±9 
months] or varied methodology [pQCT vs. MRI] between the present study and the above-
mentioned study, respectively.  
The entire cohort had muscle density values below able-bodied normative values. 
Accordingly, muscle density was low even among the individuals with above norm muscle CSA, 
implying an increased risk for obesity-related diseases regardless of muscle CSA (92). The low 
muscle density in this population was expected given a prior report of increased intramuscular 
adipose tissue (86). We found that individuals with motor complete injuries had 43% less muscle 
density than those with incomplete injuries. It is likely that the higher muscle CSA and muscle 
density among those with incomplete injuries was due to preservation from mechanical loading 
and muscle contraction during activities of daily living and perhaps resistance training. However, 
even with some muscle preservation, individuals with incomplete SCI have muscle density 
values below able-bodied norms. Decreased muscle quantity and quality puts individuals with 
both complete and incomplete SCI at risk for obesity and SLOP. For example, reductions in 
muscle CSA after SCI can result in a decreased metabolic rate and increased adipose tissue 
storage (88), and muscle atrophy has been suggested to be the largest contributor to obesity-
related complications including hyperglycemia, peripheral insulin resistance, and type II DM, 
consequently contributing to an atherogenic internal environment (91, 92). In addition, the loss 
of muscle CSA results in a decrease or cessation of physiological loading on bone; based on the 
mechanostat theory, this results in decreased bone strength and osteoporosis (30).  
Interventions that may preserve or improve muscle quantity/quality include standing, 
electrically stimulated cycling or resistance training, and walking exercises. Exercise with 
electrical simulation appears to prevent atrophy and/or increase muscle mass (315-317), but the 
impact of standing or walking exercises on muscle has not been well established (318-320). It is 
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difficult to confirm the utility of these exercises for individuals with SCI due to several 
methodological limitations such as measurement techniques, skeletal muscle measurement sites, 
and study design. Future work should take into account these limitations to facilitate practical 
and clinically relevant interventions for preserving and/or improving muscle mass. 
To our knowledge, this is the first time muscle density has been reported among individuals 
with SCI using pQCT technology. Some difficulty arose when analyzing the pQCT scans for 
muscle density. The pQCT software was designed to analyze bone characteristics, and was 
manipulated to provide muscle outcomes. As such, the Stratec XCT 2000 software was not 
sensitive enough to analyze muscle density among the entire cohort of individuals with SCI in 
the present study. In other words, the algorithm used in the software was unable to find the 
contours necessary to distinguish muscle density from adipose tissue or bone in 4 of the 12 
pQCT scans. The software was able to provide muscle density values among 8 participants (7 
men, 1 woman). No pattern was found among the scans that were analyzed vs. those that could 
not be analyzed. It may be possible to use the pQCT images and analyze them for muscle density 
using SliceOmatic software, developed specifically for tissue segmentation and body 
composition analysis. The person performing analysis can visually separate SAT from muscle 
and then use the segmentation tools to separate muscle from IMCAT, or a composite of both, to 
determine muscle density in Hounsfield Units. However, the pQCT images must be converted 
into files that SliceOmatic software can recognize. Future work should determine a means of 
converting the pQCT files, as well as ascertain an equivalent density value between pQCT and 
SliceOmatic software (mg/cm3 vs. Hounsfield Unit). 
5.2: Adipose Tissue after Spinal Cord Injury 
A high prevalence of obesity was found among the present cohort of individuals with SCI; 
our findings are consistent with previous reports in that at least two thirds of individuals with 
chronic SCI are obese (13, 14). With regards to completeness of injury, it was found that a 
greater proportion of individuals with incomplete SCI were obese when compared to motor 
complete SCI; however this difference was marginal. Other studies have reported a greater 
adipose tissue gain and lean tissue loss among individuals with motor complete SCI (67-69). A 
rationale could be that ~90% of the participants in the current study with motor complete SCI 
were paraplegic and ~70% with incomplete SCI were tetraplegic. Therefore, the individuals with 
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motor complete paraplegia may have had the capability of greater independence, accomplishing 
activities of daily living, and participation in athletic endeavors when compared to individuals 
with incomplete tetraplegia.  
Use of several accepted screening methods has confirmed a prevalence of obesity among 
individuals with SCI. Therefore, screening for obesity in this population is important, and 
subsequent action plans for intervention to prevent or reduce obesity-related complications are 
necessary. 
SCI-specific screening tools must be identified and/or combined with selected able-bodied 
tools, as able-bodied definitions for any given tool may not accurately categorize obesity. For 
example, when the able-bodied obesity definition of BMI >30 kg/m2 was employed, <20% were 
obese despite the fact that over three quarters of the participants had a % body fat in the obese 
range. A linear regression analysis of % body fat vs. BMI using the present cohort of individuals 
with SCI showed that a BMI of 22 kg/m2 was associated with ~29% body fat, and a BMI of 25 
kg/m2 was associated with ~31% body fat. These values of % body fat clearly fall within the 
definition of overweight/obesity for men of ≥23% body fat, and are close for women of ≥35% 
body fat. Other studies have found similar discontinuity between able-bodied definitions and SCI 
diagnosis (33, 54, 190). 
Whole body % fat is a dependable means of screening for obesity, as it is a more direct 
measure of body adiposity and the guidelines can be applied to any population. Two of the 15 
participants were “normal” when using the able-bodied definition of % body fat; the same 
participants plus an additional male were “normal” when applying the SCI-specific definition for 
obesity of BMI >22 kg/m2. This additional person (NLI C3-4, AIS C, DOI 29 years) deemed 
“normal” (BMI 20.92 kg/m2) had a % body fat of 37.4%. The high % body fat in this individual 
may be due to the lengthy DOI. Given the large range of functional ability among individuals 
classified as AIS C, this person may have had limited mobility below the level of lesion (high 
cervical), contributing to an adverse body composition. The discontinuity of these obesity 
definitions, even at a lowered BMI cutoff of >22 kg/m2, raises the persistent concern that BMI is 
not an ideal screening tool. When using WC as a screening tool, 8 of the 16 individuals were 
“normal”, 6 of which were obese when using % body fat.  
Ideally, % body fat should be used as the primary screening tool for obesity among this 
population. However, SCI-specific BMI and WC are more cost and time effective. Therefore, a 
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combination of cautiously interpreted SCI-specific BMI and WC may be used to detect obesity 
after SCI when % body fat is unavailable or infeasible.  
Considerable evidence supports the improvement in health outcomes even after modest 
weight loss in the general population (321). However, the value of such interventions specific to 
the SCI population is limited. Dietary interventions utilized by the able-bodied population may 
not appropriately address the special health (124, 322-324) and nutrition (325-327) needs of 
individuals with SCI. One study assessed the effectiveness of employing a 12-week intervention 
program including education on nutrition, exercise, and behaviour change, and reported small 
but significant differences in measures of obesity (BMI, WC, increased HDL-c) (328). The 
program did not strictly control for diet or exercise intervention, although it included both. 
Limited evidence exists that exercise interventions such as body weight supported treadmill 
training or functional electrical stimulation can improve indicators of obesity (329, 330).  
Aerobic and functional electrical stimulation exercise training may lead to a loss of adipose 
tissue in parallel with an increase in lean tissue, and it has been reported that habitual physical 
activity can lead to numerous health benefits that reduce the risk for multiple chronic conditions 
(331-333). Further, a recent study reported an association between greater leisure time physical 
activity and lower chronic disease risk among individuals with SCI (334). Pharmacologic or 
surgical intervention for obesity in SCI has not been reported in the literature (13). The scope of 
research on interventions specific to the persons with SCI is narrow; future research must 
evaluate the effectiveness of obesity interventions for this population. 
5.3: Bone Tissue after Spinal Cord Injury 
One hundred percent and 80% of the participants in the present study had SLOP at the distal 
femur and proximal tibia, respectively, when employing the WHO criteria of a Z-score <-2.0. 
These are the skeletal sites common to fracture. When employing a SCI-specific aBMD distal 
femur fracture threshold (below which fracture begin to occur) and fracture breakpoint (the value 
at which the majority of fractures occur), almost 80% and 50% of the participants were at risk of 
fracture. These findings agree with previous studies reporting that over 90% of fractures occur at 
the distal femur and proximal tibia in the SCI population (22, 72, 73). Only 1% of the current 
cohort was at risk of fracture based on SCI-specific vBMD distal tibia fracture threshold. The 
considerable discrepancy between detecting individuals at risk of fracture in the present study 
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using fracture threshold definitions at the distal femur (g/cm2) vs. distal tibia (mg/cm3) may be 
due to differences in population across studies. Only individuals with motor complete injures 
were included in the study proposing a distal tibia fracture threshold, whereas the study 
proposing a distal femur fracture threshold as well as the present study included individuals with 
complete and incomplete injuries. The completeness of injury has implications on lower 
extremity body composition such that individuals with motor complete injuries experience 
greater bone tissue loss (70, 71). Therefore, the participants in the study including only those 
with motor complete injuries may have had lower distal tibia vBMD, and subsequently the 
derived fracture threshold may be too low to identify individuals with incomplete injures as 
being at risk of fracture. Alternatively, the current cohort may simply be at lower risk of fracture 
than the group in which the threshold was derived, so fewer individuals in the current cohort met 
the criteria. In addition, a shortcoming of study suggesting the distal tibia fracture threshold is 
that the bone status was not measured at the time of the fracture; often the fracture(s) had 
occurred several years prior to the vBMD measurements (35). Therefore, it is difficult to 
attribute a causal association between distal tibia vBMD and fracture; perhaps the suggested 
distal tibia fracture threshold is not an accurate estimate of fracture threshold in the present 
population. A prospective study determining predictors of fracture risk and assessing fracture 
incidence in a more representative sample is necessary. 
It was found that individuals with motor complete SCI had lower aBMD at the distal femur 
and proximal tibia, as well as lower vBMD at the distal tibia when compared to those with 
incomplete SCI. These findings are consistent with the literature stating that individuals with 
complete SCI tend to lose more bone than those with incomplete SCI (70, 71). Therefore, SLOP 
and possible subsequent fractures are more common among individuals with complete injuries 
(72). The ability of muscle contraction, weight bearing, or even ambulation among individuals 
with incomplete injuries may account for the higher BMD when compared to those with 
complete injuries. 
Based on the prevalence of SLOP in the present cohort, we propose that a distal femur Z-
score and distal femur fracture threshold should be used to screen individuals with SCI for 
SLOP. Future studies should include a post-SCI fracture history to determine the prevalence of 
fracture among those individuals with aBMD values below the fracture threshold/breakpoint. A 
recent study published that health screening, fracture risk assessment, and determination of knee 
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region BMD is needed to select patients for treatment (335). The first step is to check for medical 
history and concomitant medications; any conditions or changes in medications should be treated 
before moving onto the next step. Investigating lifestyle factors (caffeine intake, smoking 
history, alcohol intake, mobility change) is the second step; education on any or all lifestyle 
factors affecting bone health should be addressed. Nutrition and bone factors (knee region BMD, 
prior fragility fracture) should then be assessed and treated with calcium and/or vitamin D 
supplements, education on fracture prevention, rehabilitation interventions, or bisphosphonate 
therapy (335). The findings from the present study of the importance in using SCI-specific 
aBMD fracture thresholds at the distal femur or proximal tibia is a critical part to this paradigm 
for treatment of SLOP and/or fragility fracture risk after SCI.  
Literature on interventions for bone health has shown preservation of bone or increases in 
BMD (257, 336-342), but none have reported sustained benefits once the intervention was 
completed. A regular physical activity program is recommended for any individuals with SCI. 
Some examples include: an aerobic and resistance training program at an accessible gym with 
knowledgeable instructors, regular standing in a standing frame, functional electrical stimulation, 
or body weight supported treadmill training. There is a need for developing interventions for 
SLOP after SCI that have clear guidelines taking into account NLI and AIS.  
5.4: Identifying Risk Factors for Obesity and Sublesional Osteoporosis 
As mentioned previously, five risk factors of sex (female) (275, 276), age (≥60 years) (153, 
277), DOI (≥10 years) (275), NLI (tetraplegia) (67, 69, 103), and AIS (motor complete) (67-69, 
235) have implications for the development of obesity and SLOP after SCI. Based on the data 
from the present cohort, ≥2 risk factors detected the majority of individuals who were at risk of 
obesity and SLOP while avoiding false positives. With a larger cohort, relative risk of each 
factor should be taken into account to better identify those at risk of obesity and SLOP. 
Based on the data from the present cohort, we propose that individuals with ≥2 risk factors 
should be screened for obesity using % body fat from DXA. Percent body fat cutoffs proposed 
by Gallagher et al., 2000 should be used to classify overweight/obesity. Future work should 
confirm if these cutoffs can be generalized to all populations, including individuals with SCI. If a 
DXA scan is not possible, a combination of a cautiously interpreted SCI-specific BMI >22 kg/m2 
and a WC >102 cm for men and >88 cm for women should be used to screen for obesity. Future 
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work should determine if SCI-specific WC is necessary. Individuals with ≥2 risk factors should 
also be screened for SLOP and risk of fracture using a distal femur Z-score <-2.0 and distal 
femur fracture threshold of <0.78 g/cm2 from DXA. Diagnosing obesity or SLOP early provides 
the opportunity to intervene in an attempt avoid cardiovascular events (i.e. stroke, heart attack) 
or fracture.  
5.5: Muscle-Bone Unit after Spinal Cord Injury 
The theoretical background for a muscle-bone relationship is provided by the mechanostat 
theory, which proposes that bones adapt their strength to keep the strain caused by physiological 
loads close to a set point (30). Since the largest physiological loads are caused by muscle 
contractions, there should be a close relationship between muscle size/strength and bone strength 
(3).  
Based on the theory of the muscle-bone unit in addition to the physiology of muscle and bone 
after SCI, we would expect to see associations between muscle CSA and bone size/shape 
variables, but not necessarily between muscle CSA and BMD, at the 1/3 proximal tibia site 
(66%). This is because the 66% site is made up mostly of cortical bone that is less metabolically 
active than trabecular bone; therefore, the reduction or cessation of physiological loading from 
muscle contractions at this site are expected to result in cortical thinning, but not necessarily a 
reduction in cortical BMD. In addition, a reduction in cortical wall thickness is characteristic of 
bone loss after SCI, whereas a reduction in cortical vBMD is not (245). Our findings are 
consistent with this theoretical and physiological explanation for a relationship between muscle 
CSA and bone size/shape variables (cortical thickness, cortical CSA) at the 1/3 proximal tibia, 
and agree with a previously reported relationship between muscle area and cortical area at the 
shaft of the radius among able-bodied men and women (307). 
A hypothesis presented by Frost in 1992 asserted that variations in the ratio between cortical 
bone area and muscle area involve different types of osteoporosis, with differing fracture risks 
(343). Although the definitions proposed are infrequently used and not verified through 
prospective studies, the type of osteoporosis may provide information as the importance of 
muscle loss on bone status of an individual or group. “Harmonic osteoporosis”, or fragility or 
disuse osteoporosis, can be defined as a cortical bone area to muscle area ratio of >0.05. This 
kind of osteoporosis implies that there is a harmonic and concordant loss of muscle and bone. 
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The second is “disharmonic osteoporosis”, or true osteoporosis, which can be defined as a 
cortical bone area to muscle area ratio <0.05. It has been suggested that this kind of osteoporosis 
primarily involves bone, and thus may be linked with a higher fracture risk (343). The present 
cohort was diagnosed with “harmonic osteoporosis” with a cortical area/muscle area ratio of 
0.0593. This agrees with the muscle-bone unit theory, as “harmonic osteoporosis” implies that 
with muscle loss, there is a harmonic and concordant loss of bone. However, the ratio is on the 
cusp, suggesting that “disharmonic osteoporosis” may also be present. This is reasonable among 
the present cohort, as individuals with SCI experience denervation to the lower extremities, 
perhaps contributing to a disproportionate loss of muscle and bone. In other words, the presence 
of “disharmonic osteoporosis” suggests that bone loss after SCI is not only due to muscle loss.   
With regards to the distal tibia site (4%), based on the theory of the muscle-bone unit and on 
the physiology of muscle and bone after SCI, we would expect to see associations between 
muscle CSA and BMD or BMC. This is because the 4% site is made up mostly of metabolically 
active trabecular bone, and is the site of muscle attachment; therefore, the reduction or cessation 
of muscle contractions will result in a corresponding decrease in BMD at this site. In addition, a 
reduction in trabecular vBMD is characteristic following SCI (245). There may also be an 
association between muscle CSA and cortical CSA, however the scanning technology used in the 
present study does not have high enough resolution to detect changes in cortical thickness at this 
site. Our findings correspond with this rationale in that associations were found between muscle 
CSA and BMD or BMC at the distal tibia; these findings are consistent with previous research 
among able-bodied persons (3).  
Given that weak to moderate associations were found between muscle and bone, it is likely 
that other factors distinct from muscle CSA contribute to bone adaptation in an atrophied state. 
Some of these other factors include: 1) mechanical loading – most of the participants were 
incomplete (AIS C-D) and could therefore perhaps weight bear or ambulate, and the participants 
who were motor complete (AIS A-B) may have spasticity and/or used a standing frame on a 
regular basis; 2) endocrine function – bone active hormones such as estrogen or testosterone; 3) 
vascular function; and/or 4) neurological function – bone denervation below the level of the 
lesion, contributing in part to “disharmonic osteoporosis”.  
Nonetheless, the results indicate that muscle atrophy contributes to a reduction in bone 
strength. The relationship between muscle and bone is clinically important, as muscle strength is 
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potentially amenable to rehabilitation intervention. The limitations of this analysis include the 
small sample size (n=41) of a large diversity of age and neurological impairment, the lack of 
adjustment for potential confounders, and the lack of a measure of functional muscle strength. 
Future research in this area should incorporate a measure of muscle strength and/or quality, and 
adjustment for potential confounders such as age, sex, serum hormone levels, DOI, NLI, and 
AIS. 
5.6: Adipose Tissue and Bone after Spinal Cord Injury 
No association was found in the present study between indices of obesity (WC, BMI, % body 
fat) and indices of SLOP (distal femur aBMD, distal tibia trabecular vBMD) among the cohort of 
individuals with SCI. However, the able-bodied literature suggests that a relationship is 
biologically plausible. Therefore, the lack of association found may be due to: 1) the limitations 
in our study of a small sample size and diversity of neurological impairment, both of which 
increase the risk of type II error, 2) the possible protective effects of hormones and/or limited 
weight bearing, or 3) simply because an association does not exist. 
To elaborate on the second reasoning, some weight bearing or ambulation in addition to a 
hormonally mediated effect may provide rationale for the attenuation of a relationship in the 
present cohort. Several studies have reported that increased mechanical loading from excess 
body weight may provide a protective effect on bone (41-43). Fifty percent of the participants in 
the present study had motor complete (AIS A-B) SCI and thus were unable to weight bear or 
ambulate, while the other 50% had incomplete (AIS C-D) SCI and thus may have been able to 
weight bear or ambulate. If the individuals with motor complete SCI experienced spasticity or 
accomplished standing on a regular basis, and if the individuals with incomplete SCI were able 
to weight bear or ambulate, these activities may have provided a partial preservation of BMD 
from gravitational or mechanical loading. 
Further, numerous studies have reported that excess adipose tissue may have a protective 
effect on bone due to hyperinsulinemia (46, 292) and enhanced production of estrogen (47-51). 
The hormones insulin and estrogen contribute to increased bone mass. The majority of adults 
with chronic SCI in the present study had excess adipose tissue, and therefore may have been in 
a state of hyperinsulinemia and/or had enhanced serum estrogen that may have provided a bone 
protective effect. In fact, a recent study reported positive associations between adipose tissue 
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mass and lower extremity bone mass among persons with chronic SCI, which they attributed to 
hormonally mediated effects (344). 
It is possible that some gravitational or mechanical loading in combination with the potential 
protective effect of enhanced hormones that contribute to increased bone mass among this 
population resulted in a null association between adipose tissue and bone. Further, the 
relationship between obesity and osteoporosis has been reported to be dependent on physical 
activity (stronger among sedentary persons) (299), and therefore the lack of adjusting for 
physical activity may have impacted our results.  
On the other hand, the body composition changes that occur after SCI in combination with 
the drastically reduced gravitational or mechanical loading provide grounds to support an inverse 
relationship between adipose tissue and bone. For those individuals with SCI who were unable to 
weight bear or ambulate, a reduction of gravitational and mechanical forces may attenuate the 
association found between body weight and bone mass. In addition, the presence of outliers may 
have influenced the association between adipose tissue and bone in the current cohort. The 
uniform removal of outliers was not planned a priori. Only one participant was identified as an 
outlier when using the criteria of a data point more than 2 standard deviations from the mean. 
This participant had a % body fat more than 2 standard deviations below the mean % body fat of 
the present cohort; this is uncharacteristically low of an individual with SCI. A combination of 
genetic factors, physical activity level, dietary intake, socioeconomic status, or DOI may account 
for the atypical % body fat in this individual with chronic SCI. When the outlier was removed, a 
trend towards an inverse association emerged, suggesting that with a larger sample size an 
inverse association may be present.  
It is well known that muscle and bone positively respond to mechanical challenges, and that 
adipose tissue increases with inactivity. On a cellular level, adipogenesis is thought to be the 
default pathway for mesenchymal stem cells that do not receive simulation to differentiate into 
other cells of osteoblasts or myocytes (345). It has been proposed that load bearing in the form of 
low magnitude mechanical signals may inhibit the differentiation of mesenchymal stem cells into 
adipocytes, as well as have an anabolic effect on bone (346). An animal study reported that after 
15 weeks, adipogenesis was inhibited by 27% among mice exposed to loading when compared to 
controls. This loading suppressed adiposity as measured by both adipose tissue mass and adipose 
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tissue volume (347). Further, another animal study reported a down-regulation of PPARγ by 27% 
following 6 weeks of low magnitude mechanical stimulus (348). 
These results suggest that it is possible that mechanical loading may facilitate the suppression 
of mesenchymal stem cells into adipocytes. Therefore in the absence of load bearing activity, 
such as after SCI, mesenchymal stem cells may differentiate into adipocytes over osteoblasts or 
myocytes. The outcome is that in the long run, adipocyte production will increase while 
osteoblast production decreases, providing a possible rationale for an inverse relationship 
between adipose tissue mass and bone mass in the absence of weight bearing.  
Recognizing a relationship between obesity and SLOP is clinically important, as obesity and 
fracture risk are potentially amenable to rehabilitation intervention. In addition, understanding 
the relationship may provide insight into mechanisms explaining why some people lose more 
bone than others, and may lead to future examination of other mechanisms for protection of 
bone. Future studies exploring the obesity-SLOP relationship among individuals with SCI will 
need to include an adequate sample size, control for variables such as DOI, NLI, and AIS, and 
account for any spasticity/regular standing among individuals with AIS A-B and any weight 
bearing/ambulation among individuals with AIS C-D. 
5.7: Limitations and Future Directions 
The disproportion of individuals in each subcategory (motor complete vs, incomplete SCI) 
based on NLI was a limitation in the present study. Only 1 individual with motor complete 
tetraplegia and only 2 individuals with incomplete paraplegia were included in the present study.  
Future studies should ensure a large enough sample size in both groups of individuals with motor 
complete (AIS A-B) and incomplete (AIS C-D) SCI to stratify based on NLI. Further, it would 
be valuable to have enough participants to stratify based on DOI, as DOI influences body 
composition changes.  
Underpowered studies can bias towards type II error, accepting the null hypothesis when the 
null hypothesis is false. The sample size in the present study is small, and includes an outlier. 
These two factors can have a large impact on assumptions drawn. For example, an r=0 was found 
between trabecular vBMD and % body fat among the present cohort of individuals with chronic 
SCI. However, when one outlier was removed, an r=0.56 (p=0.09) was found, suggesting that 
this outlier may have contributed to a null hypothesis. In addition, the small sample size 
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prevented a regression analysis evaluating muscle-bone and adipose tissue-bone relationships 
controlling for confounders. 
Physical activity is an important determinant of body composition, and the lack of a physical 
activity measure in the present study is a limitation. Obtaining a larger cohort of individuals with 
chronic SCI and including a measure of physical activity may contribute to the assessment of 
chronic disease risk in this population. A recent study conducted by a group who developed a 
self-report physical activity measure specific for individuals with SCI, reported an association 
between increased leisure time physical activity and lower chronic disease risk in adults with SCI 
(334). It may be interesting to look at the relationship between chronic disease risk and 
participation in all forms of physical activity, instead of only leisure time physical activity. In 
addition, it would be valuable to include an assessment of dietary intake among individuals with 
chronic SCI. Few studies have been conducted on dietary interventions after SCI, and to the 
knowledge of the author, no published studies to date show that a dietary intervention improves 
body composition. 
Finally, it would be valuable for future studies to include a direct measure of VAT using 
MRI in place of the indirect WC measure in the present study. The VAT value could be used to 
characterize VAT accumulation following SCI, determine obesity and obesity-related disease 
risk, and provide an index of obesity to associate with osteoporosis.  
5.8: Conclusions 
The clinical assessment of body composition in the present study demonstrates a high 
prevalence of obesity and SLOP among individuals with SCI. SCI-specific definitions for these 
chronic diseases are limited and not widely recognized. The definition and methods used to 
assess obesity, SLOP, and fracture risk will affect the number of people identified as at risk, so it 
is important to develop SCI-specific risk assessment methods that best identify high risk 
individuals. We propose that an individual should obtain a body composition assessment for 
detection of obesity and/or SLOP if he or she has ≥2 risk factors (female, ≥60 years, DOI ≥10 
years, tetraplegia, and motor complete). The body composition assessment should include a % 
body fat measure from DXA to identify the presence of obesity. A combination of a carefully 
interpreted SCI-specific BMI and WC measure may contribute to the assessment, as these 
measures are easily obtained, and the location of adipose tissue is important. The body 
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composition assessment should also include a distal femur Z-score and distal femur aBMD 
measure from DXA to detect SLOP and risk of fracture. 
Weak to moderate correlations between muscle and bone were found, even among this 
relatively small sample, providing support that muscle activity may contribute to bone strength. 
In addition, the analyzed muscle-bone relationship may provide rationale for future differential 
diagnosis between “harmonic” or disuse osteoporosis, in which the bone/muscle relationship is 
usually maintained, and “disharmonic” or other types of osteoporosis in which the 
proportionality between bone mass and muscle mass may be affected by endocrine, vascular, or 
neurological influences. No relationship between adipose tissue and bone was found in the 
current study.  
The research presented here provides a comprehensive picture of the body composition 
changes that occur after SCI in the context of the risk of chronic diseases. The results presented 
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You are being invited to participate in a research study. To decide whether or not 
you want to be a part of this research study, you should understand what is 
involved and the potential risks and benefits. This form gives detailed information 
about the research study, which will be discussed with you. Once you understand 
the study, you will be asked to sign the form at the end of this information letter if 
you wish to participate. If you are not able to sign the form but are able to provide 
verbal consent, it will be documented by the person obtaining consent. Please take 
your time to make your decision. Feel free to discuss it with your friends and 
family, or your family physician. 
 
WHY IS THIS RESEARCH BEING DONE? 
 
Individuals with spinal cord injury (SCI) often experience bone loss. Bone loss can 
cause a person to be more likely to break a bone in the future. We are conducting 
this study to examine in more detail the bone loss that occurs after SCI.  
Primary Investigators: 
Dr. Lora Giangregorio
Dr. Catharine B. Craven 
 
Co-investigators: 
Dr. A. Papaioannou 
Dr. M. Popovic 
Dr. L. Thabane 
Dr. N. McCartney 




WHAT WILL I BE ASKED TO DO IF I DECIDE TO TAKE PART IN THE 
STUDY? 
 
This study will require 10-15 hours of your time over a 2 year period.  If you 
decide to participate in the study, we will ask you to do the following things: 
Visit to Lyndhurst 
♦ Complete a medical history that asks questions about your injury characteristics 
as well as your past and current medical health, medications and lifestyle. You 
may be asked to have an ASIA exam, which tests your sense of touch and your 
sense of movement, if we do not have record of an exam for you. This will take 
approximately 45 minutes. 
♦ On your first visit to Lyndhurst, you will be asked to provide a blood sample. 
Fasting conditions will be required.  Participants will be asked to fast for at least 
12 hours.  For those participants unable to fast, a breakfast of toast and apple 
juice or orange juice will be allowed and blood will be drawn 4 hours after.  
The blood sample will be used to measure protein markers of bone metabolism, 
vitamin D, parathyroid hormone (PTH), and ionized calcium levels in your 
blood. The blood sample will be draw by a trained phlebotomist.  We will take 
about two tablespoons of blood by inserting a needle in a vein in your arm.  
♦ Participate in 1 set of 6 bone density scans. Bone density scans are x-rays that 
measure how much bone mineral you have in certain bones. Individuals with 
low amounts of bone mineral may be at increased risk of fracture. The scans 
will be taken of your hips, above and below your knee, your spine and your 
whole body. During the scans you will be transferred to a scanning table. If you 
are not able to transfer yourself, we will use a special lift device. You will not 
feel anything when the scanner is on. The scanning will take approximately 60 
minutes. 
♦ Complete some questionnaires by phone three days after your visit.  The 
questionnaires will gather information regarding your activity and diet.  This 
telephone call will last approximately 30 minutes. 
 
Visit to McMaster  
♦ Participate in a second visit at McMaster University Medical Centre for a 
second type of bone density scan.  The scanner is called a peripheral 
quantitative computed tomography scanner and also uses x-rays to measure 
bone density.  During this visit, you will be asked to participate in 1 set of 3 
scans that measure the shape and structure of your bones. A researcher will take 
3 scans, one at your ankle, the second at mid-calf and the third at the widest 
cross-section of your calf. During the scans the limb being measured will be 
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placed in a positioning device.  Please refer to the pictures we have provided. 
We will conduct the scans while you are seated in a chair or wheelchair. You 
will not feel anything when the scanner is on. This visit will take 45 minutes.  
 
Yearly Follow-up for 2 years 
♦ You will be asked to return annually for the next two years to repeat the 
medical history, bone density scans, and scans at McMaster. You will be called 
at 6 and 18 months during the two year study to monitor any changes in your 
health, medication and record if you have had any fractures.  You will also be 
asked to report any broken bones to the study coordinator over the two-year 
period when they occur.   These phone calls will take approximately 30 minutes 
or less. 
 
If you have severe spasticity: During the scans at McMaster, it may be difficult 
for the technologist to position you if you have lower body muscle spasms. Only if 
you have severe lower body muscle spasms, you will be asked to take a small 
dose of Lorazepam (otherwise known as Ativan, dose is 0.5-1.0 mg below the 
tongue) to prevent spasms while the scan is taking place. If you do not have 
severe spasticity, you will not need to take Lorazepam. Lorazepam is a short 
acting muscle relaxant that reduces muscle spasms.  Many people with SCI have 
taken Lorazepam early after their injury to help with sleeping while in hospital. 
Adverse reactions to Lorazepam, when they occur, are usually observed at the 
beginning of the dose and generally decrease in severity or disappear after 2-3 
hours.  If you become very drowsy with Lorazepam, you may not remember 
having the pQCT scan. If needed, the Lorazepam will be prescribed for you by Dr. 
Craven on the day of your scan. These precautions are taken mainly to reduce the 
chance of injury in the event that a spasm occurs when your leg is placed in the 
scanning device. You do not have to agree to take Lorazepam if you do not 
wish to do so. However, we may decide not to try to scan you if the spasticity 
limits our ability to position you safely. If you have metal implants in both lower 
legs, have broken your shinbones in the past, or have severe leg spasms and are 
allergic to Lorazepam, you will not be able to participate in the study. Also, 
women who may be pregnant or who plan on becoming pregnant cannot 
participate.  If you are a woman, a urine pregnancy test may be performed to 
ensure that it is safe for you to participate. 
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS? 
 
The risks to participants are small. Bone Density scans involve exposure to small 
amounts of radiation. The level of exposure associated with the scans proposed in 
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this study is ~30 µSv, which is less than doses received during a computed 
tomography (CT) scan of the chest (30-60µSv) or annually from background 
radiation (2500 µSv). The radiation dose is roughly equal to the dose of radiation 
received over 3 days by every Canadian from natural sources of radiation in the 
environment.  Repeated exposure to radiation has a cumulative risk over time but 
the radiation risk from participating in this study considered minimal.  
 
If you are asked to take Lorazepam to reduce your leg spasms during scans in 
Hamilton, there is a risk of side effects.  Amongst a study of 3500 people, the most 
common side effects were sedation (15.9%), dizziness (6.9%), weakness (4.2%) 
and unsteadiness walking (3.4%). Less frequent side effects include disorientation, 
depression, nausea, change in appetite, headache and agitation.  Most side effects, 
if they occur, occur with the first dose of the drug.  Lorazepam will only be given 
to you if necessary.  If you need Lorazepam, it will provided to you at no cost.  
After taking Lorazepam, the study staff will monitor you for an hour or so, to make 
sure you have not had any side effects.  A physician will be available for 
supervision. You should not drive or perform other tasks that require alertness 
immediately after taking Lorazepam. Also, you cannot take Lorazepam if you are 
currently taking the fungal medications ketoconazole (Nizoral or Xolegel) or 
itraconazole (Sporanox).   
 
Women who may be pregnant or who plan on becoming pregnant cannot 
participate in the study as there are risks to exposing a fetus or unborn baby to 
ionizing radiation. 
 
Fasting blood draws can also have side effects and discomforts.  Fasting may cause 
hunger, headache, dizziness and/or weakness.  As a result of the blood draw, there 
is a possibility that you may experience pain, bruising, bleeding or infection at the 
site of the needle puncture. Blood draws may also temporarily cause headache, 
nausea and lightheadedness. 
 
HOW MANY PEOPLE WILL BE IN THIS STUDY? 
 
80 individuals with SCI will be recruited to participate.  
 
WHAT ARE THE POSSIBLE BENEFITS OF THE STUDY FOR ME AND/OR 
SOCIETY? 
 
We cannot promise any personal benefits to you from your participation in the 
study. If you are interested in learning what your bone density is, we can send your 
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bone density scan results to your physician. The study will help us understand bone 
loss in individuals with SCI, and determine risk factors related to bone loss in SCI. 
 
CONFIDENTIALITY AND SECURITY OF DATA 
 
Your data will not be shared with anyone except with your consent or as required 
by law. All personal information will be removed from the data and will be 
replaced with a number. A list linking the number with your name will be kept in a 
secure place, separate from your file. The data will be securely stored in a locked 
office. For the purposes of ensuring the proper monitoring of the research study, it 
is possible that a member of the Office of Research Ethics at the University of 
Waterloo, Hamilton Health Sciences Research Ethics Board or Toronto Rehab 
Research Ethics Board may consult your research data and medical records. 
However, no records that identify you by name or initials will be allowed to leave 
the hospital. By signing this consent form, you authorize such access. If the results 
of the study are published, your name will not be used and no information that 
discloses your identity will be released or published without your specific consent 
to the disclosure. However, it is important to note that a copy of your signed 
consent form and the data that follows may be included in your health record.  The 
data will be retained indefinitely. 
 
CAN PARTICIPATION IN THE STUDY END EARLY? 
 
If you volunteer to be in this study, you may withdraw at any time and this will in 
no way affect the quality of care you receive at this institution. You have the 
option of removing your data from the study. You may also refuse to answer any 
questions you don’t want to answer and still remain in the study. The investigator 
may withdraw you from this research if circumstances arise which make it unsafe 
for you to continue participating and it is in your best interest to withdraw.  You 
will also be informed in a timely manner of any new information that arises during 
the course of the study that may influence your decision to participate.  
 
WILL I BE PAID TO PARTICIPATE IN THIS STUDY? 
 
You will be reimbursed $40 per visit each year ($120 in total over the course of the 
study) to assist with transportation costs to Lyndhurst or Chedoke.  For participants 
traveling to Hamilton from the Toronto area (>50km), transportation is provided 
and you are welcome to have someone accompany you on the trip.  For those 
wishing to use their own transportation for travel between Hamilton and Toronto, 
the stipend will be increased to $140 per visit.   
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WILL THERE BE ANY COSTS? 
 
Your participation in this research project will not involve any additional costs to 
you or your health care insurer. 
 
WHAT HAPPENS IF I HAVE A RESEARCH-RELATED INJURY? 
 
If you are injured as a direct result of taking part in this study, all necessary 
medical treatment will be made available to you at no cost. Financial compensation 
for such things as lost wages, disability or discomfort due to this type of injury is 
not routinely available. However, if you sign this consent form it does not mean 
that you waive any legal rights you may have under the law, nor does it mean that 
you are releasing the investigator(s), institution(s) and/or sponsor(s) from their 
legal and professional responsibilities. 
 
IF I HAVE ANY QUESTIONS OR PROBLEMS, WHOM CAN I CALL? 
 
If you have any questions about the research now or later, if you wish to withdraw 
from the study at any time or if you think you have a research-related injury, please 
contact the research coordinator for the study, Lindsie Robertson at (416) 597-
3422 x6301, pager (416) 644-6936 or one of the study investigators below: 
Dr. Craven (416)597-3422 x6122  
Dr. Lora Giangregorio (519) 888-4567 x36357 
Kayla Hummel via e-mail, khummel@uwaterloo.ca  
 
This study has been reviewed and received ethics clearance through the Office of 
Research Ethics (ORE) at the University of Waterloo, the Research Ethics Board at 
the Toronto Rehabilitation Institute and the Research Ethics Board of Hamilton 
Health Sciences/McMaster University Faculty of Health Sciences.  If you have any 
questions regarding your rights as a research participant, you may contact any/all 
of the offices listed below: 
 
Office of Research Ethics (ORE) at the University of Waterloo (519) 888-4567 
x6005  
 
Dr. Gaetan Tardif - Chair, Toronto Rehab Research Ethics Board (416) 597-3422 x 
3730 
 
Office of the Chair of Hamilton Health Sciences/Faculty of Health Sciences 
Research Ethics Board (905) 521- 2100 x42013 
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IF I DO NOT WANT TO TAKE PART IN THE STUDY 
 
It is important for you to know that you can choose not to participate in the study. 
Your doctor can do tests to look at your bone density even if you do not participate 
in this study.  Choosing not to participate will in no way affect the regular therapy 
or health care that you receive.  
 
If do not want to participate, it is important for us to know if there are significant 
differences between people who choose to participate in our study and people who 
don’t. We ask if you would mind answering 7 brief questions that will be used to 
determine if the group of people who did not participate are different than those 
who did. You can also choose not to answer these questions, it is entirely your 
decision.  If you do not want the be in the study but might want to answer the 
questions, we will review them with you and let you decide. Neither your name or 





SIGNATURE OF PARTICICIPANT/LEGALLY-AUTHORIZED 
REPRESENTATIVE 
 
I have read the preceding information thoroughly. I have had the opportunity to ask 
questions, and all of my questions have been answered to my satisfaction. I agree 




Name of Participant  
 
______________________________________  ______________ 
Signature of Participant      Date 
 
If verbal consent is obtained in lieu of a signature, the person obtaining consent 
will initial here: ______________________ 
 
 
Consent form administered and explained in person by: 
 
I confirm that I have explained the nature and purpose of the study to the 
participant name above.  I have answered all questions.  I believe the participant 
has the legal capacity to give informed consent to participate in this research study. 
 
______________________________________ 
Name and title 
 
______________________________________  ______________ 
Signature        Date 
 
SIGNATURE OF PRINCIPAL INVESTIGATOR: 
 
I have delegated the informed consent discussion to       
 
 
______________________________________  _______________ 




Access to Medical Charts 
 
 
Title of Study: Bone Quality in Individuals with Chronic Spinal Cord Injury 
Primary Investigators:  Dr. Lora Giangregorio and Dr. Catharine B. Craven 
Co-investigators: Dr. Papaioannou, Dr. Popovic, Dr. Thabane, Dr. McCartney and 
Dr. Adachi 
Sponsor: Canadian Institutes of Health Research 
 
We would like to access your medical chart to verify your medical history. We 
would like to confirm your ASIA classification to see if it has changed, check your 
surgical and medical history and see any bone density scans you have had. By 
signing below, you are giving your consent to allow the coordinator of the study 
and lead investigators to look at your chart. You have the right to choose not to 
have anyone look at your chart if that is your wish.  The information collected 
from your chart will be used for research purposes only. 
 
Consent to give access to chart at Toronto Rehab: 
 
 
________________________    ______________________    ____________ 





Participant Information Package and Consent Form 
 
TITLE OF STUDY: 
Intermittent Whole Body Vibration for Treatment of Sublesional 
Osteoporosis after Spinal Cord Injury: 
Phase II – Safety and Efficacy 
 
INVESTIGATORS: 
Dr. B.C. Craven (MD)1,2, M. Alizadeh-Meghrazi (MSc candidate)2, J. Totosy 
de Zepetnek (MSc candidate)3, L. Giangregorio (PhD)3, S.L. Hitzig (PhD)1, 
M. Miyatani (PhD)1, A. Morris (PhD)1, M. Popovic (PhD)1,2, and L. You 
(PhD)2. 
STUDY DOCTOR: Dr. Cathy Craven x6122 
RESEARCH COORDINATORS: Jude Delparte (MSc)1 x6359 
delparte.jude@torontorehab.on.ca 
RESEARCH STAFF: Stephanie Hadi1,3 
hadi.stephanie@torontorehab.on.ca 
SPONSOR: 
This study has been funded by the Ontario Neurotrauma Foundation. 
DEVICES: 
The vibrating platform was manufactured by WAVE® Manufacturing Inc., 
Windsor, ON 
The standing frame, Easy Stand 5000, was manufactured by Altimate 
Medical Inc., Morton, MN 
________ 
 
1Toronto Rehabilitation Institute 
2University of Toronto 




 You are being invited to participate in a research study. This information 
package explains the purpose of this study, provides information about the study 
devices, the tests and procedures involved, any possible risks and benefits, and 
your rights as a research participant.  
Please read all the pages in this package carefully. You may take as much 
time as you wish to make up your mind about whether or not to take part in the 
study. Ask any questions you may have before signing it. Please ask the study 
staff to explain anything you do not understand or would like to know more about.  
You will be asked to sign the consent form at the end of this package if you 
are willing to participate. You will be given a copy of this information package and 




Osteoporosis of the hips and knees is expected to develop in 85 – 90% of 
people with traumatic spinal cord injury (SCI). In people with SCI, osteoporosis 
occurs mostly in the hip and knee regions. Normally, your body continually builds 
and breaks down bone through a process called bone remodeling or bone 
turnover. After SCI, this process is interrupted causing the leg bones to become 
less dense (low bone mineral density) and more prone to fracture. Osteoporosis 
is a problem we do not see or feel until our bones break. The most common 
cause of fracture in people with SCI is rolling in their bed or during car transfers. 
There is no commonly accepted way to treat osteoporosis and prevent fractures 
in people with SCI. 
Treatments for low hip and knee region bone density after SCI include: 
standing, walking, Functional Electrical Stimulation, bisphosphonates (bone 
strengthening drugs), calcium and/or vitamin D supplements. Lifestyle 
modifications, such as smoking cessation or avoidance of alcohol, also help 
reduce the loss of bone. One prior drug study has shown to increase bone 
mineral density among subjects with SCI and low hip and knee region bone 
mineral density.  
PURPOSE OF STUDY 
The main goal of this pilot study is to see if standing in a standing frame on 
a vibrating platform 10-13 times a month has positive effects on bone turnover, 
bone mineral density and bone strength among people with SCI. We also want to 
see if standing on a vibrating platform has similar positive effects on body fat, leg 
muscles, leg blood flow, and heart disease risk, as other forms of exercise. The 
results of this pilot study may inform the design of a larger multi-centre study 
(therefore allowing for a larger study population and primary and secondary 
outcomes). 
Research into the impact of standing on a vibrating platform on bone 
health is beneficial in post-menopausal women and children with disability. 
Standing on a vibrating platform increases blood flow, and improves muscle 
strength during and after exercise in able-bodied subjects and elite athletes. 
Other benefits reported in able-bodied subjects include: decreased body fat, 
increased metabolism, increased muscle activity, and increased blood flow. 
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 No prior studies looking at the benefits of standing on a vibrating platform 
have looked at its effects on bone, fat and muscle in people with SCI. During the 
study, many tests will be done to see what harms 
or benefits, if any, vibration has on your health, 
bones, fat, heart disease risk, blood flow and 
muscles. Most of the measurements will look for 
changes in your legs over time (9 months). 
THE VIBRATING PLATFORM 
The vibrating platform used in this study is a 
modified version of a platform that is available for 
purchase in Canada called WAVE®  (WAVE 
Manufacturing Inc., Windsor, ON; 
wavexercise.com).  This device has been custom-
fitted with a standing frame (EASYStand 5000, Altimate Medical Inc., Morton, 
MN) to allow people with SCI to be able to stand on the vibrating platform.  
STUDY REQUIREMENTS & TIME COMMITMENTS 
 If you take part in this study, you will be asked to come and stand on a 
vibrating platform with the help of a standing frame about 3 times per week for 40 
weeks (9 months) at the Lyndhurst Centre (520 Sutherland Dr., Toronto ON). 
You will stand for 45 minutes at a time. The platform will vibrate on and off at 1-2 
minute intervals during this time period (45 minutes).  
Before you begin the study, we will need to make sure that it is safe for you 
to participate. You will: 1) be asked questions by phone interview; 2) allow us to 
review your health record; 3) be examined by one of the study doctors; and 4) 
have a blood test before we can tell if it is safe for you to be in the study.  
If the study doctor thinks it is safe for you to take part and you do not stand 
on a regular basis, you will need to go through a tilt-table training program. This 
tilt-table training program involves up to 5 tries to get you and your body used to 
standing again without getting dizzy. After passing the tilt-table training, you can 
start the vibrating sessions. If you are unable to successfully complete the tilt 
table training, it will not be safe for you to be in the study and you will be 
withdrawn from the study. 
During this study, we will be conducting many tests to see if there are 
short-term and long-term benefits or side effects of standing on a vibrating 
platform. These tests include:  blood test, bone density test of your whole body 
and legs, CT scan of your legs, blood flow test, and measures of leg spasticity, 
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nerve and muscle activity. A table summarizing the timing of each test is 
attached to the back of this information package (p.15). 
All of the tests will be conducted at Lyndhurst Centre except for one. We 
will arrange free transportation to the McMaster University Medical Centre via 
taxi 3 times (at the start, middle and end of the study) for a CT scan of your legs. 
The Centre is located in Hamilton, ON, at 1200 Main St. West. 
Usually your study visits will take about one hour. However, at the start, 3-
4 month time point, and at the end of the study, some visits will take up to 3 
hours. 
YOUR ROLE IN THE STUDY 
Being a research subject takes a lot of your time.  We will work hard to make it 
easy for you to be in the study. At times during the study we will ask you to: 
• Tell us about your past and current medical history, medications, over the 
counter medications and supplements.  
• Tell us about any new health problems you get during the study. 
• Tell us when you can or cannot come for visits and how to get a hold of 
you. 
This information helps to ensure your safety during the study.  
STUDY CRITERIA 
To be in this study, we need to make sure that you meet our criteria for scientific 
and safety purposes. In order to take part, you must: 
• Be male 
• Be between 20 and 55 years of age 
• Have an injury due to trauma (i.e., car accident, fall, diving, gunshot, etc.) 
for at least 2 years 
• Have a spinal cord injury between T2 and T10 which is motor complete 
(ASIA Impairment Scale of A or B) 
For safety reasons, we will ask you not to be in the study if: 
• You weigh more than 250 lbs (113kg)  
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• You are less than 5’6” (168 cm) or more than 6’2”tall (188 cm) 
• You have now or have had in the past, any of the following conditions: 
o uncontrolled autonomic dysreflexia 
o blood clots (deep vein thrombosis) 
o pressure sores on your legs or 
ankles 
o dizzy spells when standing 
(orthostatic hypotension) 
o abnormal heart beats (cardiac 
arrhythmias) 
o heart valve problems  
o an unhealed broken bone 
o a sliding vertebrae 
(spondylolisthesis)  
o joint implant (hip or knee 
replacement) 




o kidney stones 
o seizures  
o frequent migraines  
o rheumatoid arthritis 
o dislocated hip 
• You have a condition that makes it hard for you to stand safely: 
o Bone spur in the hip or knee region 
o Very stiff ankles, knees, or hips 
• You are in another study which will affect how we interpret the study 
results (e.g. Body Weight Supported Treadmill Training or Functional 
Electrical Stimulation) 
 If you have not yet done so, a Research Coordinator or a member of the 
research staff will go over these criteria with you during a telephone interview. 
Since you may not know if you have any of these conditions, you will need to see 
a study doctor at a screening visit before participating. At this visit, some of the 
above-listed criteria will be compared to your medical records. 
SCREENING VISIT 
 A screening visit will be done for you and the study doctor to see if it is 
safe for you to be in the study. At this visit, you will meet the Research 
Coordinator and a member of the research staff. They will make sure that all of 
your questions about the study are answered. They will ask you to sign the 
consent form at the end of this information package. After talking about the study 
and signing the consent form, the screening visit will take 2-3 hours.  
During or after the screening visit you will be asked to: 
• Fill out a few surveys – these ask about your age, gender, type of SCI, 
education & employment, medications, functional abilities (SCIM 
questionnaire), medical history, frequency and severity of muscle spasms 
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(SFSS form), type and frequency of health issues related to your SCI (SCI-
SCS questionnaire), and activity levels (PARA-SCI Questionnaire). 
• Answer questions about your medical history. 
• Have a blood test to ensure your hemoglobin and vitamin D blood levels 
are in the normal range.  
• Be examined by a study doctor to verify the type of SCI you have, grade 
any pressure sores (NPUAP form), and record the range of motion and 
spasticity in your legs (if any).  
• An ultrasound of the kidneys and bladder to ensure you do not have any 
kidney stones or gallstones. 
• An X-ray of the spine to ensure that you do not have any loose or broken 
hardware.  
If you had an ultrasound of your kidneys in the 3 months before the study 
or spine X-ray 6 months prior, you do not have to have these tests. 
 Once all the test results (bloodwork, X-ray and ultrasound) come back, we 
will let you know if you are suitable/eligible for the study and when you can try the 
tilt-table program, if needed. 
TILT-TABLE PROGRAM 
 The tilt-table program will help your body get used to 
standing again without becoming dizzy or lightheaded. You 
will have up to five tilt table sessions over a two-week period. 
While on the tilt table, we will check your heart rate, blood 
pressure and symptoms. If after five tries your blood pressure 
is too low, your heart rate is too high, or you feel too dizzy, 
you will not be able to be in the study. Each tilt-table session 
will be less than one hour. If you complete the tilt table 
program in two or three visits, the training will stop.  
VIBRATION SESSIONS 
 Each time you come, you will transfer into the standing frame and then the 
platform will vibrate you. The vibration will occur at 45 cycles per second (45Hz), 
and move you vertically 0.6mm for 1 minute at a time followed by 2 minutes of 
rest until 45 minutes have gone by.  You will be asked to come to 3 vibration 
sessions a week or 10-13 times per month for nine months (40 weeks).  We hope 
you will come to a total of 120 vibration sessions. Preliminary data in 10 able-
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bodied men and 4 SCI subjects has shown that the vibration settings used in this 
study are safe for use with people with SCI. 
 Your blood pressure (BP) and heart rate (HR) will be monitored before, 
after and every 15 minutes during the sessions. If your BP or HR goes out of 
range, we will ask you to take a break from the vibration and may ask you to stop 
the vibration session that day if your BP or HR does not come back to normal. 
Someone will be present at all times to assure your safety and help you with 
transfers, if needed. Each visit, we will ask you if you had any of the following 
side effects during the vibration sessions:  
• Inner ear troubles • Pain 
• Dizziness • Itching 
• Blurred Vision • Headache 
 All participants in the study will be given a free pair of shoes (Crocs™) to 
wear during the vibration sessions. These shoes are being used to make sure 
that everyone participating in the study has a similar material on their feet 
between them and the vibrating platform. The shoes are yours to keep after the 
study. 
 If you miss a few sessions due to illness, you can stay in the study. If you 
miss too many sessions so that your study data is hard to interpret, you will no 
longer be in the study. A study team member, or Dr. Craven, will talk to you 
about this issue if it comes up.  
ENTRY AND EXIT MEASUREMENTS 
Since we want to see how your bone, muscle and fat changes during the study, 
you will be asked to have many tests at the beginning and end of the study. The 
following tests/actions will be done over the course of 2 or 3 visits before and 
after the 9 months of vibration (total of 4-6 measurement visits): 
• Two-dimensional bone and body composition scan (DXA) 
• Three-dimensional bone, fat, and muscle leg scan (pQCT)*** 
• Blood test to look at bone health and metabolism  
• Urine test of bone turnover (urine sample) 
• Assessment of spasticity (Ashworth, SFSS questionnaire, pendulum test) 
• Assessment of blood flow in your trunk and legs (PWV) 
• Nerve activity (H-Reflex) 
• Muscle activity (EMG) 
• Measurement of your weight, height and waist circumference 
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*** Please note that pQCT will be conducted at McMaster University Medical 
Centre (1200 Main St. West, Hamilton, ON) which is about 85km from the 
Lyndhurst Centre. 
BLOOD DRAWS AND URINE SAMPLES 
Blood and urine will be collected on days when you are coming for a vibration 
session and will add about 15 minutes to your visit. We will draw your blood and 
ask for a urine sample to test at the start of the study, 3 months, 6 months, and 9 
months (end of study).  
On the days that you come in for blood work, we will ask that you fast (no eating) 
starting at 11:00pm the night before. All blood measures will be done between 
10:00am and 12:00pm. We will ask that you bring a small snack so that once the 
blood work has been completed, you may eat a little bit before the vibration 
session. If you have diabetes, we will allow for you to take some of your 
medications with water and a piece of bread. At the start of the visit, we will take 
up to five tubes of blood (30mL = 6 tablespoons) while during other visits we will 
take four tubes of blood (25mL = 5 tablespoons).  
We will ask you to bring in your first morning urine to us. We will give you a 
container to collect it in before you need it.  Urine samples will be used to look for 
indicators of bone health. Blood drawn will be analyzed for indicators of sugar 
and lipid metabolism and bone health. We will give you a list of all the indicators 
upon request. You will not see the blood and urine results until after the study is 
over. We will give you a list of all the results after the study is over, if you would 
like. 
MEASUREMENTS OF BLOOD FLOW 
Blood flow will be measured by using a method 
called pulse wave velocity (PWV). PWV is the 
speed at which blood pressure waves travel in the 
arteries within your body. It is a simple, painless 
way of measuring the stiffness of your arteries. For 
this test you will be asked to fast (no eating) for 6 
hours and to avoid alcohol, caffeine, and nicotine 
for 12 hours before the test. You will also be asked 
not to do any heavy exercises during this time 
period. During the PWV test, you will rest on your 
back for about 20 minutes in a quiet room. Two 
small sensors will be held on your skin to 
determine the flow rate between 1) your neck and 
groin, 2) groin and ankle, and 3) your upper arm and wrist. 
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PWV will be measured before and after vibration at the start, end and 3 month 
time points. Each time, PWV will be measured 2 times per visit: before vibration 
and again 20 minutes after vibration. PWV will also be measured before the 
regular vibration sessions start. It will be measured in response to standing in a 
standing frame for 45min without vibration. On days when PWV is measured, you 
will be at the Lyndhurst Centre for 2 more hours than a regular visit. 
TWO-DIMENSIONAL BONE AND BODY COMPOSITION 
 You will be asked to have a 
whole body bone density and body 
composition scan at the start, 4  
month time point and end of the 
study. Bone density scans are x-
rays that measure how much bone 
mineral you have in your bones. 
The scans will be taken of your 
hips, above and below your knee, 
your spine and your whole body. 
During the scans you will be transferred onto the scanning table. If you are not 
able to transfer yourself, we will use a lift. You will not feel anything when the 
scanner is on. This test will take about 45 minutes. The machine does the work 
to measure your muscle and bone mass from one set of scans. 
THREE-DIMENSIONAL BONE, MUSCLE & FAT COMPOSITION 
 These visits will take place at McMaster 
University Medical Centre (Hamilton, ON). The visit 
will take about 30 minutes for the scan plus your 
travel time to Hamilton. The study will pay the cost 
for each of the three visits for you to go to Hamilton 
via wheelchair taxi and take you home after the scan 
is done. These tests will be done at the start, at the 
4-month time point, and at the end of the study. 
 During this visit, you will have one set of three scans that measure the 
shape and structure of your bones with a scanner called peripheral quantitative 
computed tomography (pQCT shown). For these scans, your leg will be 
positioned in the scanning device and held there with a strap at the ankle and 
plastic holder at the knee. A researcher will take three scans, one at your ankle, 
the second at mid-calf, and the third at the widest cross-section of your calf. We 
will conduct the scans while you are seated in a chair or your wheelchair. You will 
not feel anything during the scans. People with thick calves or severe spasticity 
may find this test hard or impossible to do. 
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If the diameter of your right calf is greater than 14 cm, or you have a metal 
implant in your right calf, or have broken your shinbone in the past, or have 
severe leg spasms and are allergic to lorazepam (Ativan), you will not be able to 
have the peripheral quantitative computed tomography test done.  This will not 
affect your ability to be in the study. 
 During the peripheral quantitative computed tomography scans, it may be 
difficult for the technologist to position you if you have leg spasms. If you have 
severe leg spasms, you will be given a small dose of lorazepam (0.5-1.0 mg 
below the tongue) to prevent spasms while the scan is taking place. Lorazepam 
is a short acting muscle relaxant that reduces muscle spasms.  Many people with 
SCI have taken lorazepam early after their injury to help with sleeping while in 
hospital.  If needed, the lorazepam will be prescribed for you by Dr. Craven and 
given to you by her or the hospital pharmacist on the day of your scan.  
These safety measures are taken to reduce your chance of injury if a 
spasm occurs when your leg is in the scanning device.  You do not have to agree 
to take lorazepam.  However, we may decide not to do the scan if your spasticity 
limits our ability to position you safely. 
If you need lorazepam to reduce your leg spasms during the pQCT scans, 
there is some risk of side effects.  Amongst a study of 3500 people, the most 
common side effects were sedation (15.9%), dizziness (6.9%), weakness (4.2%) 
and unsteadiness walking (3.4%). Less frequent side effects include 
disorientation, depression, nausea, change in appetite, headache and agitation.  
Most side effects, if they occur, occur with the first dose of the drug.  Lorazepam 
will only be given to you if necessary.  If you need lorazepam, it will be provided 
to you at no cost.  After taking lorazepam, the study staff will monitor you for an 
hour or so, to make sure you do not have any side effects.   
If you do not take lorazepam regularly, you should not drive or perform 
other tasks that require alertness for two hours after taking lorazepam. Also, you 
cannot take lorazepam if you are currently taking the fungal medications called 
Ketoconazole or Itraconazole. 
H-REFLEX 
 An electrode will be placed on the skin of your calf muscle to measure the 
Hoffman reflex or H-reflex. The H-reflex is a measure of how the muscle reacts to 
a small electric current. To measure this reflex, we will stimulate the nerve with 
an electric current that will gradually increase in intensity until your muscle 
contraction is visible or you ask us to stop. During this test you may feel a 
stinging sensation behind the knee where the electrode is placed. H-reflex will be 




We will look to see how your leg muscles respond to vibration from the 
platform. To measure your leg muscle activity, four pairs of electrodes or sensors 
will be placed on your skin over the front and back of the thigh and calf (upper 
and lower leg). To make sure we get a good signal, your skin will be prepared by 
washing it with a cleansing gel and then rubbing it gently with fine sandpaper. 
The sensors will be connected to an electromyogram (EMG) which will record the 
electrical activity of your muscles when standing and vibrating. You will be asked 
to wear suitable clothing for the study (i.e. athletic clothing, track pants/shorts, 
and not jeans). Muscle activity will be measured in months 1 and 9 and will add 
about 30 minutes to your regular vibration session on these two days. 
SPASTICITY ASSESSMENTS 
Three separate spasticity tests will be performed: Modified Ashworth Scale, 
SFSS and Pendulum test with shape tape. The three tests will be done before and 
after your vibration session at the start, 3 month time point and end of the study. 
The MAS test is scored by a trained rater using a 5-point scale.  You will lie on 
your back on a plinth while they test the spasticity of your legs, including the hip 
abductors, hip adductors, hamstrings, quadriceps, and ankle plantar and 
dorsiflexors.  During the Pendulum test with shape tape, we will tape a cable to 
the side of your leg, drop the lower half of your leg off the edge of a table, and 
watch it swing until it stops, a computer will record the rate your leg drops and 
how quickly it stops moving. The SFSS is short questionnaire that you will be 
asked to answer about how often and how bad your spasms are. The three tests 
take 15 minutes to complete. 
WAIST CIRCUMFERENCE 
A measuring tape will be used to measure your waist while laying down. 
You will be asked to roll up your shirt so that the measurement can be taken in line 
with your lowest rib by a research staff member. This will take 1-2 minutes to do 
the measurement and record the value. We will measure this at the start of the 
study, after 4 months, and at the end of the study. 
ACCELERATION 
We want to know how far vibrations from the device travel up your legs. This 
has been measured in able-bodied people who have normal muscle tone in their 
legs. We are interested in finding out if the vibrations travel through the body 
differently in people with SCI who have increased muscle tone in their legs. To do 
this, we will use four accelerometers. These accelerometers are small boxes 
connected to a computer that measure movement. They will be attached to your 
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leg at the ankle, knee, hip and forehead with the use of tape and a headband. We 
will do this in the first month and the ninth month. 
INTERVIEW 
At the start of the study, you will be asked to do a 30 minute interview about 
your reasons for being in the study and your expectations of the device. Again at 
the end of the study, you will meet with the same interviewer who will ask you 
about your experiences during the study, if you find it has benefited you, and if you 
have any comments about the device. 
POSSIBLE BENEFITS  
We cannot promise any personal benefits to you from your participation in 
this study. However, your participation may help other people with SCI in the 
future. Individuals with SCI who have participated in standing programs have told 
us they benefited. They told us they had reduced spasticity, improved bowel and 
bladder function, fewer digestive complaints, less pain and lower limb swelling, 
and better hip range of motion. 
POSSIBLE RISKS AND DISCOMFORT 
 Because no one has done a study like this one, we may not know about 
some risks. There are some risks we do know about, they are listed below: 
Vibration 
 Vibration causes side effects. The known side effects of vibration include: 
inner ear problems, dizziness, headache, worsening of existing lower limb 
spasticity, fracture, or short-term loss of hearing. Although we think it is possible 
but it has never been seen before, your hardware could loosen. If this happens, 
the Study Doctor will refer you to a spine surgeon. 
 If you have had in the past or develop any of the following conditions it will 
not be safe for you to be in the study: chronic migraine headaches, kidney 
stones, cochlear implant, deep vein thrombosis, irregular heart beat, cancer, 
heart valve disease, rheumatoid arthritis, gallstones, pacemaker, joint implant, 
diabetes, pregnancy, or seizure.  
There may be some extra risks when you are vibrated without having 
eaten for a while. These include light-headedness, dizziness, and fainting 
because of low blood sugar. During each vibration session, we will have juice 




 The bone density (DXA) and computed tomography (CT) scans involve 
small amounts of radiation. The level associated with the scans proposed in this 
study is ~26µSv for each set of bone density scans and ~1µSv for the CT scans. 
Since the bone density and CT scans are performed three times during the study 
the total dose is ~80µSv. This is about the same as getting one chest X-ray (30-
60µSv). Compared to what you usually get exposed to naturally over a year 
(2500 µSv), this is very little. Radiation exposure adds up but the total radiation 
dose from the study scans is low and has minimal risk.  
Standing 
 Possible side effects related to standing include, but are not limited to the 
following: autonomic dysreflexia, low BP, pain, a broken bone, skin breakdown or 
pressure sores, and swollen feet and/or ankles.  
 There is a chance that you might get a pressure sore on your knees or feet 
during the study. We will regularly check your knees and feet for pressure sores 
and if present record their severity with the National Pressure Ulcer Advisory 
Panel Pressure Ulcer Scale. If you develop a sore we will refer you to our skin 
and wound clinic for advice and monitoring.  
Blood Draws 
 You may get pain during the blood draws or a bruise at the site where the 
needle goes in. There is a small risk of infection after a needle stick. You may 
need to have more than one needle stick to draw your blood. 
Pulse Wave Velocity 
 You might be uncomfortable during the PWV testing as a staff member will 
place the ultrasound device on your neck and groin area. We will try to make this 
as comfortable as we can. Very few people were worried by this in prior studies. 
Electrodes 
 Sometimes, we have to shave a small area of the skin where the electrode 
is applied if you have hairy legs. 
Again, there may be some side effects of which we are likely unaware. We 
have used vibration and standing in a previous study with rare serious side 
effects (1 in 60 patients). Please report any side effects or discomforts if they 




YOUR RIGHT TO ASK QUESTIONS 
You may ask questions about this consent form or the study, now or at any 
time during the study. If you have questions about this study or if there are any 
problems or injuries associated with this study, you may call Dr. Craven at (416) 
597-3422 x6122.  
If you have questions regarding your rights as a research subject that you 
wish to discuss with someone not involved with the study but who has reviewed 
the study, you may call Dr. G. Tardif, Chair, Research Ethics Board at (416) 597-
3422 x3730. 
COST OR PAYMENT TO YOU 
There will be no charge for taking part in this study or for any of the tests 
performed. Taking part in this study will not change the way you pay for your 
health care. You will not be paid to take part in this study. You will get $10.00 per 
study visit to cover some of your transportation expenses to Lyndhurst Centre 
(travel/parking). You will receive payment for each visit at the end of each month 
of participation in the study. If you decide to drop out of the study, you will be 
paid for the visits you attended.  
RIGHT TO WITHDRAW FROM STUDY 
Taking part in this study is your choice (voluntary). You may refuse to be in 
this study. You have the right to withdraw from this study at any time, and for any 
reason. Withdrawing from this study will not affect your medical care or your 
ability to take part in future research at Toronto Rehab.  
It is also important for you to know that the investigators may decide not to 
use some of your data from the study if there is not enough data to analyze. 
Additionally, if at any point the study doctor(s) decides that starting or continuing 
in this study would be harmful to you, you will be asked to withdraw from the 
study.  
If you decide to withdraw from the study before completion, you may be 
asked if we could collect some final data. We hope that you will at least agree to 
have a spinal X-ray to make sure that the vibration did not loosen any hardware. 
If you should decide to withdraw from this study or are asked by your 
family doctor to leave the study, you are encouraged to contact the study doctor 
Dr. B.C. Craven immediately at (416) 597-3422 x6122 or the Research 




 Your study data will not be shared with anyone except with your consent or 
as required by law. All personal information will be removed from the data and 
will be replaced with a number. A list linking the number with your name will be 
kept in a secure place, separate from your file. The data will be securely stored in 
a locked office. For the purposes of ensuring the proper monitoring of the 
research study, it is possible that a member of the Toronto Rehabilitation Institute 
Research Ethics Board may review your research data and medical records. 
However, no records that identify you by name or initials will be allowed to leave 
the hospital.  
 By signing this consent form, you authorize such access. If the results of 
the study are published, your name will not be used and no information that 
discloses your identity will be released or published without your specific consent 
to the disclosure.  
 Dr. B.C. Craven or a delegate will store a paper and electronic (computer) 
copy of your results for seven years. These results will not be part of your 
hospital chart. Dr. B.C. Craven or a delegate will review your medical records, if 
necessary, to verify the information collected. Sponsors and manufacturers will 
not have access to the data generated in this study until it is in its published form. 
 At your request, we will share the study purpose and or your study results 
with your treating physician during or after the study. 






     Week 
    Screen 0 1 13 17 20 26 40 41+ 
Screening                   
  Verbal Consent X                 
  Pre-screening Form X                 
  Informed Consent X                 
Safety Assessments                   
  Medical History (HO) X                 
  Physical Exam (Contractures) X                 
  Kidney Ultrasound X                 
  Bladder Ultrasound X                 
  Spinal X-ray X               X 
  Serum Screening (blood test) X                 
  Tilt-table X                
  Pressure sores score X               X 
  Current Medications X X X X   X X X X 
  Adverse Events X X X X   X X X X 
  Accelerometry     X         X   
Bone Outcomes                   
  Bone Biomarkers    X   X     X   X 
  DXA – bone scan   X    X       X 
  pQCT – bone scan   X    X       X 
Metabolic Syndrome and CAD                   
  MetS Biomarkers (blood test)   X   X           
  Pulse Wave Velocity   X X     X     X 
  Blood pressure/Heart Rate  X     X       X 
Adiposity                   
  pQCT – muscle and fat scan   X     X       X 
  DXA - body composition scan   X     X       X 
  Waist Circumference  X     X       X 
  BMI (height, weight)  X     X       X 
Spasticity (muscle stiffness)                   
  Ashworth test   X   X         X 
  Pendulum Test   X   X         X 
  Stiffness Questionnaire   X   X         X 
Neuromuscular Function                   
  sEMG (muscle activity sensors)     X         X   
  H-Reflex     X         X   
Questionnaires                   
  SCIM-III X               X 
  SCI-SCS X               X 
 PARA-SCI  X        
Qualitative Interview          
 SCI Subjects  X       X 





TITLE OF STUDY: Intermittent Whole Body Vibration for Treatment of Sublesional 
Osteoporosis after Spinal Cord Injury: Phase II – Safety and Efficacy 
 
I have read this consent form. My questions regarding this study have been 
answered. I voluntarily consent to take part in this study involving the treatment and 
procedures described above, with an understanding of the known possible risks that 
might occur, and recognizing that not all such risks may be completely known. I am 
aware that I may not benefit directly from taking part in this study. 
 
By signing this consent form I am not giving up any legal rights. I also understand 
that nothing in this consent form is intended to change any applicable federal, 
provincial or local laws regarding informed consent. I will receive a copy of this 
consent form to keep. 
 





My Name (Please print) 
 
 
_________________________________   __________  
 







Printed Name of Person Obtaining Informed Consent 
 
 
_________________________________   __________ 
 
Signature of Person Obtaining Informed Consent     (Date) 
 
 
